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A greater understanding of hematopoietic stem cell (HSC) regulation is required for dissecting protective
versus detrimental immunity to pathogens that cause chronic infections such asMycobacterium tuberculosis
(Mtb). We have shown that systemic administration of Bacille Calmette-Guérin (BCG) or b-glucan reprograms
HSCs in the bone marrow (BM) via a type II interferon (IFN-II) or interleukin-1 (IL1) response, respectively,
which confers protective trained immunity against Mtb. Here, we demonstrate that, unlike BCG or b-glucan,
Mtb reprograms HSCs via an IFN-I response that suppresses myelopoiesis and impairs development of pro-
tective trained immunity to Mtb. Mechanistically, IFN-I signaling dysregulates iron metabolism, depolarizes
mitochondrial membrane potential, and induces cell death specifically in myeloid progenitors. Additionally,
activation of the IFN-I/iron axis in HSCs impairs trained immunity to Mtb infection. These results identify an
unanticipated immune evasion strategy of Mtb in the BM that controls the magnitude and intrinsic anti-
microbial capacity of innate immunity to infection.
INTRODUCTION
During infection or stress, hematopoietic stem cells (HSCs) inter-
rupt dormancy and adapt to meet the peripheral demand for im-
mune cells via their expansion and differentiation into more line-
age-restricted progenitors, primarily within the bone marrow
(BM). This process must be tightly controlled to avoid dysregu-
latedHSC activation, whichmay lead to exhaustion and compro-
mise the systemic immune compartment (Essers et al., 2009;
Hartner et al., 2009; Sato et al., 2009). Infection-specific changes
in hematopoiesis may restrict or promote generation of specific
lineages to centrally bias the overall systemic immune response.
For instance, we recently demonstrated that exposure of BM
HSCs to Bacille Calmette-Guérin (BCG) or b-glucan (a compo-
nent of the fungal cell membrane) results in their reprogramming
to promote myelopoiesis and protect against Mycobacterium
tuberculosis (Mtb) infection in a type II interferon (IFN-II)- or inter-
leukin-1 (IL1)-dependent manner, respectively (Kaufmann et al.,
2018; Moorlag et al., 2020). Thus, safeguard mechanisms must
exist to ensure maintenance and survival of the HSC pool and
their commitment toward myelopoiesis.
Although initially confined to cells of the lymphoid lineage,
memory-like responses have now been described extensively
for myeloid cells in a process called trained immunity (Netea
et al., 2020). The short lifespan of innate immune cells, however,
limits the effectiveness of this protective response against
chronic infections. Others (Mitroulis et al., 2018) and we (Kauf-
mann et al., 2018; Moorlag et al., 2020) have demonstrated
that trained immunity is driven by HSC epigenetic imprinting,
which can be transmitted to BM-derived macrophages. Thus,
imprinting of innatememory signatures in HSCs appears to over-
come the limitation of the short half-life mature innate cells.
Although protective trained immunity is well documented, it
may also manifest deleteriously. For example, the persistent
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Figure 1. Mtb-i.v. Induces HSC Expansion and Suppresses Myelopoiesis
(A) The i.v. model.
(B, C, and H–R) WT mice were challenged i.v. with Mtb, Mtb-DRD1, or BCG.
(B) Survival (n = 6–8 mice/group).
(C) BM CFUs (n = 4–10 mice/group).
(D–G) In vitro infection of BM cells with H37Rv- or BCG-GFP (4 h, MOI 3). Shown are ImageStream (D) and flow cytometry (F) analysis of infected cells, as a
percentage of parental cells in (E) and (G).
(H) Fluorescence-activated cell sorting (FACS) plots and quantification of LKS cells (n = 4–8 mice/group).
(I) Percentage of Ki67+ LKS cells on day 7.
(legend continued on next page)
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hyperactive state of trained innate cells can trigger tissue
damage or chronic inflammation upon exposure to endogenous
ligands (Bekkering et al., 2014; Leentjens et al., 2018) or path-
ogen-associated molecular patterns (PAMPs) (Wendeln et al.,
2018), suggesting that the stimulus, localization, and cell type
are crucial for promoting development of protective versus
detrimental rewiring. Although exposure of HSCs to certain path-
ogens and/or PAMPs appears to be an important step for gener-
ation of protective trained immunity, themechanistic basis of this
process as well as its longevity remain largely unknown.
IFN-I (IFN-a and IFN-b) and IFN-II (IFN-g) are critical for regu-
lation of HSC activation (Baldridge et al., 2010; Essers et al.,
2009) and are also involved in generation of epigenetically medi-
ated innate memory responses (Kamada et al., 2018). Although
chronic exposure of HSCs to IFN-I (Sato et al., 2009) or IFN-II
(Matatall et al., 2016) causes exhaustion, IFN-II signaling is
also required for HSC proliferation at steady state (Baldridge
et al., 2010) and promotion of myelopoiesis in systemic BCG
vaccination (Kaufmann et al., 2018) or malaria infection (Belyaev
et al., 2010). Although these cytokines are involved in regulating
survival and expansion of progenitors, they do not appear to
directly induce HSC lineage commitment. Rather, cell death ap-
pears to be a keymechanism by which HSC and progenitor pop-
ulations promote lineage biasing. For instance, during bacterial
infection, IFN-I signaling inhibits HSC expansion via necroptosis
(Smith et al., 2018), whereas overexpression of the anti-
apoptotic proteins BcL-xL (Dolznig et al., 2002) and Bcl-2 (Aka-
shi et al., 1997) rescues erythropoiesis in erythropoietin-deficient
mice and lymphopoiesis in IL-7R-deficient mice, respectively.
However, the molecular mechanisms involved in HSC fate deci-
sions are incompletely understood.
Iron (Fe) is a vital micronutrient that supports fundamental
cellular functions in most living organisms, where regulation of
Fe metabolism emerged evolutionarily to form a conserved
host defense strategy (Hood and Skaar, 2012; Soares and
Weiss, 2015). During chronic Mtb infection, the host minimizes
Fe availability to inhibit bacterial growth (Olakanmi et al., 2007;
Parrow et al., 2013), and major alterations in Fe metabolism
lead to susceptibility to tuberculosis (TB) (Gangaidzo et al.,
2001; Murray et al., 1978). Yet, the potential contribution of Fe
to HSC lineage decisions during infection is unknown.
Considering that BCG reprograms HSCs toward myelopoiesis
and generates protective trained immunity against Mtb (Cirovic
et al., 2020; Kaufmann et al., 2018), we investigated whether
the presence of virulent Mtb in the BM affects innate immunity
to infection. Here we show that, although access of Mtb to the
BM changes the transcriptional landscape of HSCs andmultipo-
tent progenitors (MPPs) similarly to BCG, the magnitude of the
IFN-I and heme metabolism pathways significantly differed be-
tween BCG and Mtb. In contrast to BCG, Mtb induced RIPK3-
dependent necroptosis in myeloid progenitors downstream of
HSCs via an IFN-I/Fe axis, which led to reduced myelopoiesis
and failure to generate trained immunity against TB. Importantly,
the protective or detrimental signatures of BCG and Mtb on
HSCs were maintained for1 year, respectively. Thus, our study
indicates thatMtb accesses the BM to target innate immunity by
imprinting HSCs with a unique transcriptomic profile that sup-
presses myelopoiesis and impairs innate immune control of
Mtb infection.
RESULTS
Systemic Mtb Differentially Modulates Hematopoiesis
Compared with BCG in a Region of Difference 1 (RD1)-
Dependent Manner
Although it has been shown previously thatMtb can disseminate
to the BM in diverse TB patients (Das et al., 2013), the effect of
Mtb in the BM in comparison with BCG on HSC proliferation,
fate decision, trained immunity, and disease pathogenesis re-
mains unknown. To investigate this, we began by determining
the effects of the same dose (1 3 106 colony-forming units
[CFUs]) of intravenous BCG andMtb (H37Rv) (Figure 1A) on sur-
vival, BM bacterial loads, and hematopoietic cell responses in
wild-type (WT) mice. Although all intravenous BCG (BCG-i.v.)
and control mice survived,Mtb-i.v. mice succumbed to infection
by 120 days (Figure 1B). Mtb-i.v. rapidly accessed the BM and
persisted until at least 28 days post-infection, coinciding with
the earliest onset of mortality. At these time points, BCG and
Mtb entered the BM and replicated similarly (Figure 1C). As
shown previously with BCG-GFP (Kaufmann et al., 2018), Mtb
(H37Rv-GFP) was unable to infect Lin c-Kit+ Sca-1+ (LKS) cells,
whereas Lin+ cells were readily infected, as evidenced by Image-
Stream (Figures 1D and 1E) and flow cytometry (Figures 1F and
1G). Thus, any effect of these mycobacteria on HSCs must be
indirect.
To quantify these potential effects, we directly compared the
effect ofMtb-i.v. and BCG-i.v. on HSC and MPP kinetics (gating
strategy in Figure S1A). Mtb or BCG in the BM correlated with
significant expansion of the LKS population until at least
28 days post-infection (Figure 1H). LKS expansion was associ-
ated with proliferation, as shown by the increased frequency of
Ki67+ LKS cells in Mtb-i.v. mice compared with BCG-i.v. and
control mice on day 7 (Figure 1I) and was not due to an increase
in long-term HSCs (LT-HSCs) but, rather, short-term HSCs (ST-
HSCs) and MPPs (Figures S1B–S1D). Despite a more rapid
response in Mtb-i.v. compared with BCG-i.v. mice on day 7
post-infection, by day 28, the numbers of HSCs and MPPs
were similar in two groups (Figures S1B–S1D). BCG-i.v. protec-
tion againstMtb correlates with HSC skewing toward myelopoi-
esis by enhancing the pool of myeloid-biased MPP3s rather than
lymphoid-biased MPP4s (Kaufmann et al., 2018). Unexpectedly,
despite the greater virulence ofMtb compared with BCG, the dy-
namics of MPP3 versus MPP4 were indistinguishable between
(J–L) Frequencies (top) and totals (bottom) of CMPs (J), GMPs (K), and CLPs (L) (n = 4–13 mice/group).
(M–R) Total BM LKS cells (M); LT-HSCs, ST-HSCs, MPPs, CMPs, GMPs, and CLPs (N); MDPs (O); cMoPs (P); GPs (Q); and Ly6Chi monocytes (R) on day 28.
Log-rank test (B), two-way ANOVA followed by Sidak’smultiple comparisons test (C, H, and J–L), one-way ANOVA followed by Tukey’smultiple comparisons test
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BCG-i.v. and Mtb-i.v. (Figures S1B–S1D). Thus, both bacteria
access and persist equally in the BM to regulate HSC responses.
LKS cells give rise to all hematopoietic cells, including com-
mon myeloid progenitors (CMPs) and common lymphoid pro-
genitors (CLPs), which lead to mature leukocytes. Because the
plasticity between MPPs is high (Lai and Kondo, 2006; Pietras
et al., 2014), lineage restriction is more stringently completed
downstream at the CMP/CLP level (Akashi et al., 1997; Kondo
et al., 1997). We next investigated how i.v. Mtb or BCG affected
lineage-restricted progenitors. As with LKS cells (Figure 1D),
neither Mtb nor BCG infected cKit+ myeloid progenitors (Fig-
ure S1E). Despite this, on day 7 and continuing on days 14 and
28 post-infection, Mtb, but not BCG, significantly suppressed
myelopoiesis and promoted lymphopoiesis via loss of CMPs
and granulocyte-monocyte progenitors (GMPs) and expansion
of CLPs (Figures 1J–1L). Then we sought to investigate how
Mtb, in contrast to BCG, caused these hematopoietic changes.
RD1 is present in all virulent strains of Mtb but absent in BCG.
Deletion of this region (H37Rv:DRD1) results in attenuation of
Mtb that resembles BCG in cultured macrophages and mice
(Lewis et al., 2003; Sherman et al., 2004). To see whether RD1
was responsible for the alterations in hematopoiesis, we infected
mice with H37Rv:DRD1 and found no difference between
Mtb-DRD1,Mtb, and BCG in expanding LKS or HSCpopulations
28 days post-infection (Figures 1M, 1N, and S1F–S1H).
However, skewing of hematopoiesis by Mtb was completely
dependent on RD1 expression because BCG and Mtb-DRD1
were indistinguishable (Figures 1N and S1G), whereas Mtb
significantly suppressed myelopoiesis and promoted lympho-
poiesis compared with Mtb-DRD1 (Figure S1H).
Downstream of CMPs/GMPs, granulocyte progenitors (GPs)
give rise to neutrophils, whereas macrophage/dendritic cell pro-
genitors (MDPs) and common monocyte progenitors (cMoPs)
differentiate into all cells of the mononuclear phagocyte lineage
or Ly6Chi monocytes, respectively. Correlating with the reduc-
tion in CMPs/GMPs, on day 28 post-Mtb infection, we observed
a significant reduction in the frequency and number of MDPs,
cMoPs, and GPs and the number of mature Ly6Chi monocytes
and neutrophils (Figures 1O–1R and S1I–S1M). Therefore, loss
of myeloid progenitors leads to loss of mature myeloid cells in
the BM.
Under stress, the spleen can contribute to extramedullary he-
matopoiesis (Bronte and Pittet, 2013). To investigate whether the
spleen may compensate for the suppressed BM myelopoiesis
during systemic Mtb infection, we phenotyped splenic progeni-
tors on day 28 after BCG-i.v. orMtb-i.v. FollowingMtb infection,
we observed a smaller proportion of LKS cells in the spleen than
in the BM that was equal between groups (Figure S1N) and,
similar to BM, exhibited loss of CMPs/GMPs and expansion of
CLPs (Figure S1O). Thus, Mtb appears to universally regulate
hematopoiesis to restrict myelopoiesis.
Mtb Uniquely Reprograms HSCs and Impairs Trained
Macrophage Immunity
Because of the similar responses at the cellular level in HSCs but
divergence at the progenitor level, we postulated that Mtb
transcriptionally reprogrammed HSCs to modulate downstream
progenitors. To test this, we performed bulk RNA sequencing
(RNA-seq) on HSCs (LKS+CD150+) and MPPs (LKS+CD150)
isolated on day 28 post- BCG-i.v.,Mtb-i.v., or PBS-i.v. (control).
For MPPs and HSCs, the first principal component (PC1) of gene
expression data explained over 40% of the total variance and
segregated Mtb-i.v. versus BCG-i.v. or PBS control mice (Fig-
ure 2A; one-tailed t test, p = 0.023 and 5.1 3 107 for HSCs
and MPPS, respectively). Accordingly, we found extensive dif-
ferences in gene expression levels between Mtb-i.v. and BCG-
i.v. compared with PBS control mice (Figure 2B; Mtb-i.v. versus
control: 1,282 [10.6%] and 2,952 [24.3%] differentially ex-
pressed genes (DEGs) in HSCs and MPPs, respectively; BCG-
i.v. versus control: 1,793 [14.8%] and 2,646 [21.8%] DEGs in
HSCs and MPPs, respectively; Table S1; false discovery rate
[FDR] < 0.01). Regulation of gene expression by Mtb and BCG
was highly concordant in MPPs and HSCs (Figure 2C; Pearson
correlation of Mtb-i.v. versus BCG-i.v. effects: 0.751 and 0.837
in HSCs and MPPs, respectively, p < 1 3 1010 in both) as well
as the Gene Ontology terms enriched among genes that signifi-
cantly changed expression levels in response to Mtb or BCG
(Figure S2A; Pearson correlation of significance levels: r = 0.68
[HSCs], r = 0.77 [MPPs], p < 1 3 1010). Globally, DEGs in
BCG-i.v. or Mtb-i.v. infection were strongly enriched for gene
sets involved in IFN-I and IFN-II responses, T cell activation, pro-
liferation, and glycolysis (Figure S2B; Table S2), suggesting that
the presence of mycobacteria in the BM led to IFN-dependent
rewiring of HSCs and MPPs, consistent with our previous report
(Kaufmann et al., 2018).
Despite the overall similarities in the gene expression
response of HSCs and MPPs to BCG and Mtb, we found signif-
icant differences in genes that respond to Mtb-i.v. or BCG-i.v.
689 of these infection-responsive genes in HSCs and 402 in
MPPs showed significant differences in expression across my-
cobacteria (FDR < 10%; Table S1). Gene set enrichment ana-
lyses (GSEAs) showed that genes involved in IFN-I signaling,
glycolysis, and inflammation were significantly enriched among
genes more highly expressed in response to Mtb-i.v. compared
with BCG-i.v. (Figure 2D; Table S3). In contrast, DEGs following
BCG-i.v. versus Mtb-i.v. were enriched for those involved in
heme metabolism (Figure 2D). These data, suggested that
intrinsic differences in the transcriptional magnitude of pathways
involved in IFN-I signaling and heme in HSC/MPP populations
might be transmitted to the more committed progenitors and
effector cells, modulating their numbers and/or function.
To test the potential contribution of these transcriptional
changes in HSCs on the functional capacity of innate immunity,
we next generated bonemarrow-derivedmacrophages (BMDMs)
from BCG-i.v., Mtb-DRD1, Mtb-i.v., and PBS mice and infected
themwithMtb (Figure2E). Toensure that therewasnocontamina-
tionwithmycobacteria from the in vivo infection, we cultured cells
with anti-TB drugs, and all BMDM cultures wereMtb or BCG free
at the time of in vitro infection (Figure 2G). Similar to the results of
in vivo myelopoiesis (Figures 1J, 1K, and 1O–1R), Mtb-i.v. mice
generated fewer BMDMs than BCG-i.v. or Mtb-DRD1-i.v. mice
relative to control mice (Figure 2F). Moreover, despite culturing
the same number of BMDMs in each group prior to in vitro Mtb
infection, BMDMs fromMtb-i.v. mice failed to controlMtb growth
on day 5 post-infection in an RD1-dependent manner (Figure 2G).
As expected, BMDMs derived from BCG-i.v. mice showed
ll
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enhancedprotectionagainstMtb infection.Althoughweobserved
a decrease in the number of BMDMs generated in the Mtb-i.v.
group (Figure 2F), the purity and activation levels (CD80, CD40,
andmajor histocompatibility complex [MHC] class II) were similar
(Figures S2C–S2F). Therefore, the impaired training of BMDMs in
theMtb-i.v. group is not due to the presence of immature cells or
contaminationbyother cell types.To investigatewhether thisphe-
nomenon required constant exposure to the bacteria in vivo, we
treated BCG-i.v., Mtb-i.v., and control mice with anti-TB drugs
for 28 days, followed by 2 weeks of rest. BM and BMDM cultures
were free ofmycobacteria (MtborBCG). BMDMs from thesemice
were then infected with Mtb in vitro (Figure S2G), and again,
BMDMs from Mtb-i.v. mice showed impaired capacity to control
Mtb growth (Figure S2H).
Finally, to assess the functional anti-Mtb capacity of BMDMs
in vivo, we performed adoptive transfers. We differentiated
BMDMs in the presence of anti-TB drugs from the PBS, BCG-
i.v., and Mtb-i.v. groups on day 28, infected the BMDMs
in vitro with Mtb, and transferred them (intratracheally) into
RAG1-deficient mice (lacking B and T cells) (Figure 2H). As
observed previously (Kaufmann et al., 2018), BMDMs from the
BCG-i.v. group provided enhanced protection after 21 days (Fig-
ure 2I). However, mice that received BMDMs from the Mtb-i.v.
group had significantly higher bacterial burdens in the lungs
Figure 2. Mtb-i.v. Imprints a Unique Transcriptional Signature in HSCs and Detrimentally Trains BMDMs
(A) Principal-component analysis (PCA) of gene expression of HSCs and MPPs from the BM of PBS, BCG-i.v., and Mtb-i.v. mice after 28 days.
(B) Number of genes differentially up- or downregulated in HSCs and MPPs (FDR < 0.01).
(C) Scatterplots of genome-wide effect sizes in HSCs (top) and MPPs (bottom).
(D) GSEA of DEGs (FDR < 0.1).
(E) BMDM model.
(F) Relative BMDM yield.
(G) CFUs from in vitro Mtb-infected BMDMs (n = 7–10 mice/group).
(H) Adoptive transfer model.
(I) Lung CFUs post-transfer.
In (F) and (I), one-way ANOVA followed by Tukey’s multiple comparisons test was used. In (G), two-way ANOVA followed by Sidak’s multiple comparisons test
was used. In (E)–(I), data are pooled from 2–3 independent experiment. See also Figure S2.
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Figure 3. Aerosolized Mtb Disseminates to the BM and Expands LKS Cells
(A) Aerosol model used in (B)–(U).
(B) BM CFUs.
(C and D) Representative FACS plots of LKS cells as quantified in (D) as frequency (left) and total number (right).
(E–I) Representative FACS plots (E) of LT-HSCs (F), ST-HSCs (G), MPPs (H), and MPP3/4 (I) (n = 4–10 mice/group).
(J–N) Total CMPs (J), GMPs (K), and CLPs (L) (n = 4–8 mice/group) and MDPs (M) and GPs (N) on day 120.
(legend continued on next page)
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than PBS and BCG-i.v. mice. This difference was observed
despite the number of Mtb in macrophages from the BCG-i.v.
group being slightly higher than in the PBS orMtb-i.v. group prior
to transfer (Figure S2I). Thus, Mtb, in contrast to BCG, sup-
presses myelopoiesis to impair the generation and intrinsic anti-
mycobacterial capacity of BMDMs in vitro and in vivo, uncover-
ing a novel strategy of Mtb pathogenesis in the BM.
Pulmonary Mtb Infection Suppresses Myelopoiesis and
Prevents Trained Immunity
The systemic model ofMtb infection does not represent the nat-
ural route of infection in humans. To extendour findings to aphys-
iological model of pulmonary TB, we infected mice with a low
dose of Mtb via the aerosol route (Figures 3A and S3A). Within
10–14 days following aerosolizedMtb infection, bacteria dissem-
inate to the lung-draining lymph nodes by infected dendritic cells
and/or monocytes, leading to T cell priming (Chackerian et al.,
2002; Samstein et al., 2013; Wolf et al., 2008). Interestingly, we
found that Mtb also reached the BM 10 days post-infection and
grewuntil the last timepoint analyzed at 120days,when the num-
ber of Mtb in the BM was close to the i.v. model (Figure 3B). As
with the i.v. model, this was associated with expansion of LKS
cells (Figures 3C and 3D), ST-HSCs, and MPPs but not LT-
HSCs (Figures 3E–3H and S3B–S3D). Moreover, aerosolized
Mtb skewed hematopoiesis toward MPP3 (Figure 3I and S3E).
In the lineage-restricted progenitors, we again observed a reduc-
tion of CMPs/GMPs and expansion of CLPs (Figures 3J–3L and
S3F–S3H) as well as a significant loss in the numbers of MDPs
and GPs (Figures 3M and 3N) and a trending decrease in cMoPs
(Figure S3I). This reduction of myelopoiesis led to a decreased
number of mature neutrophils and Ly6Chi monocytes in the BM
on day 120 compared with uninfected cells (Figures S3J and
S3K) as well as loss of Ly6Chi monocytes from peak levels (day
14 versus 120) in the lungs, whereas T cells increased continually
(Figures S3L–S3N). Thus, Mtb enters the BM and suppresses
myelopoiesis regardless of infection route, and hematopoietic
biasing may contribute to driving the shift in the pulmonary im-
mune response from innate to adaptive immunity.
Next we sought to characterize, at single-cell resolution, the
transcriptional response of HSCs and progenitor cells at
120 days of Mtb aerosol infection. To do so, we performed
droplet-based single-cell RNA-seq (scRNA-seq) (Zheng et al.,
2017) on sorted BM LKS cells and cKit+ progenitors. Following
quality control, we kept a total of 5,698 high-quality LKS cell tran-
scriptomes (LKS dataset: 2,388 derived from control and 3,310
derived from the Mtb group) and 5,745 transcriptomes from
cKit+ cells (progenitor dataset: 2,241 PBS and 3,504 Mtb). LKS
cells were classified into six clusters based on known canonical
markers as well as DEGs between subsets of LKS cells (Cabe-
zas-Wallscheid et al., 2014; STARMethods; Figure S3O): a clus-
ter of long-term HSCs (HSC-LT), three clusters of short-term
HSCs (HSC-ST_A, B, and C), one cluster of lymphoid-biased
MPP4, and one cluster of myeloid-biased MPP3 (Figures 3O
and 3Q). Among cKit+ cells, we identified two clusters of
CMPs, four clusters of GMPs, and three clusters of megakaryo-
cyte-erythrocyte progenitors (MEPs) (Figures 3P, 3Q, S3P, and
S3Q). In accordance with the flow cytometry data, we observed
an expansion of ST-HSCs (up to log2(OR) = 3.3 in HSC-ST_C, p <
2.2E16) and reduction of monocyte precursors (GMP_MonPs,
log2(OR) =1.2, p < 1E7) in theMtb group compared with PBS
(Figures S3R and S3S).
The gene expression across all clusters was markedly
changed between cells derived from Mtb infected and control
mice (Table S4). LKS cells were the most responsive to Mtb
infection (Figure 3R, top panel), showing between 506 (HSC-
ST_A) and 2,269 DEGs (HSC-ST_B) (FDR < 5% and absolute
fold change R 0.1). Aerosolized Mtb also largely affected the
transcriptional profile of cKit+ cells, ranging from 203 DEGs
among MonPs (cluster GMP_MonP) and 851 DEGs among
CMP_MegP (Figure 3R, bottom panel).
Despite differences in the number of DEGs identified within
each cell type—which, in part, reflects differences in statistical
power because of differences in cell numbers (Figure S3T)—the
response to aerosolized Mtb was concordant across all cell
types, with stronger correlations among cell types that are func-
tionally more related. For example, the correlation in the tran-
scriptional response to Mtb between MPP3 and MPP4 cells
was 0.76 (p < 2.2E16) compared with only 0.48 (p < 2.2E16)
between MPP3 and LT-HSCs (Figure S3U). GSEA revealed that
the two pathways most enriched among genes upregulated in
response to aerosolizedMtb were the IFN-II and IFN-I pathways
(enriched in all clusters; normalized enrichment score [NES]
across clusters ranges from 1.51–3.23, FDR < 0.05) (Figure 3S).
Stat1, a key TF involved in the response to IFN, was significantly
upregulated in response toMtb in virtually all clusters (Figure 3T),
further highlighting the importance of IFN signaling in reprogram-
ing HSCs and progenitors. As with Mtb-i.v. infection, this
imprinting in the BM correlated with loss of in vitro control of
Mtb by BMDMs from aerosol Mtb-infected mice (Figure 3U).
AerosolMtb also imprints HSCs/progenitors to blunt myelopoie-
sis and generate macrophages that fail to control Mtb growth.
IFN-I Signaling Restricts Myelopoiesis and Impairs
Macrophage Responses to Confer Susceptibility to Mtb
Infection
The RNA-seq analyses indicated that Mtb significantly modu-
lated IFN. IFN-II is critical for HSC expansion and myelopoiesis
(Baldridge et al., 2010; Belyaev et al., 2010; Kaufmann et al.,
(O and P) UMAP dimensionality reduction plots for LKS+ (O) and cKit+ (P) cells.
(Q) Hematopoietic tree with approximate position of the different clusters identified (color code in common with O and P).
(R) Number of genes up- and downregulated in each cluster (abs(logFC) > 0.1 and FDR < 0.05).
(S) GSEA of genes ranked according to Mtb effects in each cluster.
(T) Stat1 expression across clusters.
(U) BMDMs from mice infected with Mtb for 120 days were infected in vitro and CFU quantified (n = 3 mice/group).
One-way ANOVA followed by Tukey’s multiple comparisons test (B, D, and F–L), two-tailed Student’s t test (M and N), and two-way ANOVA followed by Sidak’s
multiple comparisons test (U) were used. Data are representative of two (B and J–N) or three (C–I) independent experiments. See also Figure S3.
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2018), whereas IFN-I induces loss of stem cell numbers and
function (Pietras et al., 2014; Smith et al., 2018). Interestingly,
duringMtb infection, IFN-II signaling is essential for host survival
(Nandi and Behar, 2011), whereas IFN-I signaling is detrimental
(Antonelli et al., 2010). Thus, we wondered whetherMtb-induced
IFN-I directly affected lineage commitment and BMDM anti-
microbial responses. Following aerosol or i.v. Mtb infection,
Ifnar1/ mice exhibited enhanced survival (Figures 4A and 4B)
and a significant increase in CMPs and GMPs but no difference
in CLPs compared with the WT (Figures 4C–4E and S4A–S4F).
Thus, additional factors other than IFN-I promote lymphopoiesis
during Mtb infection.
It has been shown that IFN-I signaling impairs macrophage
anti-Mtb immunity (Mayer-Barber et al., 2014) and also en-
hances susceptibility to Mtb infection via recruitment of permis-
sive BM-derived CCR2+ monocytes into the lungs (Antonelli
et al., 2010). Thus, we investigated how IFN-I signalingmay regu-
late BMDM trained immunity. Mtb-i.v. infected Ifnar1/ mice
had an enhanced in vitro BMDM yield compared with WT Mtb-
i.v. mice (Figure 4F), and, using either our ex vivo (Figure 2E) or
in vivo model (Figure S2G), the lack of protection by BMDMs
from Mtb-infected mice was entirely dependent on IFN-I
signaling (Figures 4G and 4H).
To determine the specific role of IFN-I in hematopoiesis, we
used a model of systemic IFN-I production through the intraper-
itoneal administration of the TLR3 synthetic viral ligand polyino-
sinic:polycytidylic acid (poly(I:C)). The effects on hematopoiesis
were then assessed on days 3 and 7 post-poly(I:C) treatment
(Figure 4I; Smith et al., 2018). In line with previous reports (Pietras
et al., 2014), an increase in BM IFN-I was observed in mice
shortly following poly(I:C) administration (Figure S4G). Similar
to Mtb, poly(I:C) increased the LKS/ST-HSCs/MPPs but not
LT-HSCs (Figures 4J–4N and S4H–S4J) and decreased CMPs
while increasing CLPs (Figures 4O, 4P, S4K, and S4L).
Poly(I:C)-treated WT mice also displayed reduced MDPs,
cMoPs, and GPs as well as Ly6Chi monocytes and neutrophils
(Figures S4M–S4Q). As expected, all effects were entirely IFN-I
dependent, as revealed in Ifnar1/ mice (Figures 4J–4P and
S4H–S4Q). As with Mtb-infected mice, BMDMs from poly(I:C)-
treated WT mice showed IFN-I-dependent impaired resistance
to Mtb (Figure 4Q). Thus, IFN-I signaling inhibits myelopoiesis
and prevents generation of protective trained immunity.
To contrast the effect of poly(I:C) on suppression of the
myeloid lineage and trained immunity, we next used b-Ggucan
(Figure 4R), which has been shown to promote myelopoiesis (Mi-
troulis et al., 2018; Moorlag et al., 2020). b-Glucan-treated mice
showed enhanced LKS cells/LT-HSCs/ST-HSCs/MPPs 7 days
post-treatment (Figures S4R–S4U) and myeloid CMPs/GMPs
(Figures S4V and S4W) with no changes in CLPs (Figure S4X).
We generated BMDMs from b-glucan-treated or PBS mice and
infected them with Mtb in vitro. BMDMs from b-glucan-treated
mice protected against Mtb infection via an IFN-I-independent
(Figure 4S) but IL-1-depedent mechanism (Moorlag et al.,
2020). Remarkably, the effect of b-glucan was long lived in vivo
with aerosol Mtb infection; 60% of b-glucan-treated mice sur-
vived up to 500 days (Figure 4T). There are multiple signaling
pathways involved in hematopoietic stem and progenitor cell
imprinting to promote myelopoiesis and generate protective
trained immunity (e.g., IFN-II or IL-1) or suppress myelopoiesis
and generate impaired trained immunity (e.g., IFN-I) againstMtb.
IFN-I Signaling Modulates Iron Metabolism to Limit
Myelopoiesis and Enhance Susceptibility to Mtb
IFN-I signaling has been shown to regulate progenitor cell death
during bacterial infection (Smith et al., 2018), and cell death pro-
grams are critical in HSC lineage decisions (Kanayama et al.,
2017). Thus, we investigated whether cell death limited myelo-
poiesis. Necrosis was significantly increased in CMPs/GMPs of
Mtb-i.v. infected compared with BCG-i.v. mice (Figure 5A) but
not in CLPs (Figure S5A). Interestingly, the expression levels of
Ripk3, a key mediator of necroptosis (Vandenabeele et al.,
2010), were increased significantly in HSCs from Mtb-i.v. but
not BCG-i.v. mice (Figure 5B), which led us to speculate that
the observed necrosis of CMPs/GMPs was RIPK3 dependent,
as suggested by previous reports (Smith et al., 2018; Yamashita
and Passegue, 2019). The numbers of CMPs/GMPs/CLPs in
naive WT and Ripk3/ mice were similar (Figures S5B–S5D).
However, 7 days post-Mtb infection, Ripk3/ mice had signifi-
cantly increased frequencies and numbers of CMPs and GMPs
compared with WT mice, with no effect on CLPs (Figures 5C–
5E and S5E). Thus, Mtb induces RIPK3-mediated necroptosis
in myeloid progenitors.
Our HSC RNA-seq revealed an enrichment for heme meta-
bolism in BCG-i.v. compared with Mtb-i.v. mice (Figure 2D).
Figure 4. Mtb Suppresses Myelopoiesis and Impairs Innate Training in an IFN-I-Dependent Manner
(A and B) Survival following (A) aerosol (n = 6–7 mice/group) or (B) i.v. (n = 8–9 mice/group) infection.
(C–E) Total CMPs (C), GMPs (D), and CLPs (E) after i.v. infection.
(F) Relative BMDM yield.
(G) In vitro BMDM CFUs with Abx in culture.
(H) In vitro BMDM CFUs with Abx in vivo.
(I) Poly(I:C) model.
(J and K) Representative FACS plots of LKS cells as quantified in (K) with percentages (left) and totals (right).
(L–P) Total LT-HSCs (L), ST-HSCs (M), MPPs (N), CMPs (O), and CLPs (P).
(Q) In vitro BMDM CFUs.
(R) b-Glucan model.
(S) In vitro BMDM CFUs (n = 6–7 replicates/group).
(T) Aerosol survival (7 mice/group).
In (A), (B), and (T), log rank test was used. In (C)–(E), (G), (H), (K)–(Q), and (S), two-way ANOVA followed by Sidak’s multiple comparisons test was used. In (F), one-
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Figure 5. IFN-I Regulates Fe Metabolism in Myeloid Progenitors and Triggers Necrosis
(A) Frequencies of necrotic (NucSpot+ AnnexinV) CMPs (left) and GMPs (right) on day 7.
(B) Ripk3 expression in HSCs.
(C–H) Mice were infected i.v. for 7 days.
(C–E) Percentage (left) and total (right) of CMPs (C) and GMPs (D) and total CLPs (E).
(F) CMPs with disrupted MMP.
(G) Relative mitochondrial Fe2+ in CMPs.
(H) Representative histograms (left) and quantification (right) of CMP CD71 expression.
(I–L) WT and Ifnar1/ mice were infected i.v. for 28 days.
(I) Representative histograms (left) and quantification (right) of CMP CD71 expression.
(J) Percentage of necrotic CMPs.
(legend continued on next page)
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Interestingly, dysregulation of Fe/heme metabolism in HSCs
leads to oxidative stress through free radical generation (e.g.,
H2O2) and HSC ablation (Muto et al., 2017), whereas reduction
in the cellular iron pool causes mitochondrial dysfunction and
myeloid cell death (al-Rafaie et al., 1994; Martin-Sanchez et al.,
2017). Thus, we postulated that Mtb disrupts Fe metabolism to
limit myelopoiesis. We first found that necroptosis was accom-
panied by mitochondrial dysregulation in CMPs (Figure 5F) but
not in CLPs (Figure S5F). This correlated with a reduction in mito-
chondrial Fe content in CMPs of Mtb-i.v. versus BCG-i.v. mice
(Figure 5G) but not in CLPs (Figure S5G) and a concordant upre-
gulation of the transferrin receptor (CD71), which plays a critical
role in Fe import (Ganz, 2013; Figure 5H). This was at least partly
IFN-I dependent because the levels of CD71 expression in CMPs
and CLPs (Figures 5I and S5H) as well as the frequency of
necrotic CMPs were also reduced significantly in Mtb-infected
Ifnar1/ mice (Figure 5J). Additionally, the mitochondrial Fe
level (Figure 5K) and mitochondrial membrane potential (MMP)
(Figure 5L) remained equal to uninfected Ifnar1/mice, confirm-
ing the importance of IFN-I signaling in CMP Fe metabolism.
Similarly, the expression levels of CD71 were increased signifi-
cantly in CMPs but not CLPs after poly(I:C) treatment in WT
mice (Figures 5M and S5I). This was associated with Fe accumu-
lation in the BM (Figure 5N) along with a reduction in mitochon-
drial Fe (Figures 5O and S5J) and MMP (Figures 5P and S5K)
in CMPs, but not CLPs, in an IFN-I-dependent fashion. Loss of
mitochondrial potential was furthermore linked to accumulation
of mitochondrial reactive oxygen species (ROS) and necrosis
in CMPs but not CLPs (Figures 5Q, 5R, S5L, and S5M). Similar
results were obtained following aerosol infection (Figures
5S–5V).
Having established that IFN-I signaling modulated Fe meta-
bolism specifically within myeloid progenitors to induce necro-
sis, we next investigated whether disruption of Fe metabolism,
using an inducible mouse model of ferritin H chain (FTH) defi-
ciency (Blankenhaus et al., 2019), dysregulated hematopoiesis
and/or trained immunity afterMtb infection. Whole-body tamox-
ifen-inducible Fth deletion via Cre recombinase activity under the
ROSA26 promoter in adult mice (referred to as FthD/D mice) (Fig-
ure 6A) is lethal shortly after tamoxifen administration (Blanken-
haus et al., 2019). Although the cause of death in FthD/D mice
has been shown to be due to altered thermogenesis (Blanken-
haus et al., 2019), we also found that the hematopoietic system
was severely compromised because CMPs, GMPs, and CLPs in
FthD/D mice were reduced significantly in comparison with
R26Cre and Fthfl/fl control mice (Figures 6B, 6C, and S6A). This
suggests that FTH is essential to sustain hematopoiesis. To
overcome the short life expectancy of FthD/Dmice, we generated
BM chimeric mice in which FTH is deleted specifically in the he-
matopoietic compartment, allowing us to investigate the role of
FTH in hematopoietic cells. Lethally irradiated WT (CD45.1+)
mice reconstituted with ROSA26CreERT2Fthlox/lox BM (CD45.2+)
received tamoxifen (BM-Fth/) or vehicle (BM-Fth+/+) for
5 days (Figures 6D and 6E). Similar to Mtb-infected or
poly(I:C)-treated mice, in BM-Fth/ mice, the frequency and to-
tal number of CMPs (Figure 6F) were decreased significantly,
which correlated with reduced mitochondrial Fe2+ (Figure 6G)
and mitochondrial depolarization (Figure 6H). However, the fre-
quency, but not total number, of CLPs was increased signifi-
cantly (Figure S6B), and no alterations in mitochondrial Fe
were observed (Figure S6C). Strikingly, this dysregulation of
myelopoiesis in BM-Fth/ mice had a substantial effect
on anti-mycobacterial responses because BMDMs from BM-
Fth/ mice failed to control the growth of virulent Mtb but not
avirulent BCG (Figures 6I and S6D). This was relevant in vivo
because, similar to mice lacking FTH in myeloid cells (Reddy
et al., 2018), BM-Fth/ mice were severely susceptible to aero-
solMtb infection, exhibiting significantly increasedMtb growth in
the BM, lungs, liver, and spleen (Figures 6J, 6K, S6E, and S6F)
and succumbing to death within 50 days (Figure 6L). This
occurred despite largely normal myeloid cell frequencies in the
lungs, BM, and spleen prior to infection (Figures S6G–S6I).
These results collectively indicate that dysregulation of the
IFN-I/iron axis severely impairs myelopoiesis and causes sus-
ceptibility to Mtb infection.
Mycobacterium-Mediated Functional Rewiring of BM-
HSCs and Progenitors Is Maintained up to at Least
1 Year
Our results indicate that BCG reprograms HSCs, ultimately lead-
ing to trained immunity and increased protection against TB. In
contrast, Mtb induces regulatory changes in HSCs that fail to
induce trained immunity and lead to BMDMs with impaired con-
trol of Mtb. HSC exhaustion in the BM has been reported in hu-
man TB patients since the 1980s (Hunt et al., 1987), but howMtb/
BCG may modulate the long-term (LT) functional capacity of
(K) Relative mitochondrial Fe2+ in CMPs.
(L) CMPs with disrupted MMP.
(M–R) WT and Ifnar1/ mice were treated with poly(I:C) for 3 days.
(M) CMP CD71 expression.
(N) Representative micrographs (left) and total puncta (right) of BM Perl’s Prussian Blue; the scale bar represents 50 mM.
(O) Relative mitochondrial Fe2+ in CMPs.
(P) CMPs with disrupted MMP.
(Q and R) Frequency of ROS+ (Q) or necrotic (R) CMPs.
(S–V) WT mice were infected with aerosolized Mtb for 120 days.
(S) Representative histograms (left) and quantification (right) of CMP CD71 expression.
(T) CMPs with disrupted MMP.
(U and V) Percentage of necrotic CMPs (U) or GMPs (V).
In (A) and (F)–(H), one-Way ANOVA followed by Tukey’s comparison test was used. In (C)–(E) and (S)–(V), two-tailed Student’s t test was used. In (I)–(R), two-way
ANOVA followed by Sidak’s, Tukey’s, or Dunnett’smultiple comparisons test was used. Data are representative of two (A and F–I) independent experiments or are
pooled from 2–3 individual experiments (M–R). See also Figure S5.
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HSCs is unknown. To directly compare the reconstitution capac-
ity of mycobacterium-exposed BM, we performed a competitive
mixed chimera experiment. Lethally irradiated mice were recon-
stituted with mixed BM cells (50/50) of Mtb (CD45.1+), BCG
(CD45.2+), or PBS (either CD45.1+ or CD45.2+) and treated
with antibiotics for 4 weeks to eliminate mycobacteria and then
rested for 2 weeks (Figure 7A). Beginning at 4 weeks and
continuing every 4 weeks until 16 weeks post-reconstitution,
when LT-HSC-dependent hematopoiesis is established, we
analyzed the percentage of CD45.1+ and CD45.2+ cells in pe-
ripheral blood. At 16 weeks, in the PBS:PBS group, the fre-
quencies of CD45.1+ compared with CD45.2+ donor cells in all
leukocyte populations tested were equal (Figures S7A–S7D,
left panels), excluding any potential artificial bias in engraftment
of CD45.1+ cells compared with CD45.2+ cells. However,
although the proportion of circulating leukocytes was compara-
ble in the Mtb:PBS group (Figures S7A–S7D, second panel), the
BCG:PBS and BCG:Mtb groups showed a significant bias to
be derived from BCG-i.v. mice (Figures 7B, 7C, S7A, and S7B,
right panel, and S7C and S7D, third and fourth panels). This
was due to superior engraftment of BCG-exposed HSCs
because at 16 weeks post-reconstitution, BCG-derived HSCs
Figure 6. Iron Dysregulation in the BM Promotes Susceptibility to TB
(A) FthD/D model.
(B and C) Percentages (left) and numbers (right) of CMPs (B) or GMPs (C).
(D) BM-Fth/ model.
(E) BM ferritin immunoblot; actin = loading control.
(F) Percentage (left) and total (right) of CMPs.
(G and H) Relative mitochondrial Fe2+ (G) or disrupted MMP (H) in CMPs.
(I) In vitro BMDM CFUs.
(J and K) BM-Fth+/+ or BM-Fth/ mice were infected with aerosolized Mtb for 28 days. Shown are BM (J) and lung (K) CFUs.
(L) Aerosol survival (n = 5 mice/group).
One-way ANOVA followed by Tukey’s multiple comparisons test was used in (B) and (C). Two-tailed Student’s t test was used in (F)–(H), (J), and (K). Two-way
ANOVA followed by Sidak’s multiple comparisons test (I) or log rank test (L) was used. Data are pooled from two experiments (B and C) or representative of two
independent experiments (E, F–H, and I). See also Figure S6.
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and progenitors as well as effector leukocytes in the BM and
lungs, dominated BCG:Mtb chimeras (Figures 7D–7J and S7E–
S7K). Thus, BCG-exposed HSCs exhibit superior engraftment
compared with control or Mtb-exposed HSCs, indicating that
BCG reprograms HSCs to enhance their functional capacity.
To further explore the durability and length of HSC imprinting
following exposure to mycobacteria, we next employed a serial
engraftment model. CD45.2+ mice were infected with Mtb,
BCG, or PBS control for 4 weeks, treated with anti-mycobacte-
rial drugs for 4 weeks, and rested for 2 weeks. BM from each
groupwas transplanted into lethally irradiated CD45.1+mice (pri-
mary engraftment). After 16 weeks, BM was re-harvested and
transplanted into a second group of lethally irradiated CD45.1+
mice (secondary engraftment) (Figure 7K). After 20 weeks, no
mycobacteria could be found in the BM (Figure S7L), and there
was a significant reduction in total myeloid cells in the blood as
well as Ly6Chi monocytes and neutrophils in the recipients of
Mtb-i.v. BM (Figures S7M–S7O). In line with the reduced leuko-
cytes in the circulation, the HSC compartment of the recipients
of Mtb-i.v. BM had fewer LKS cells, LT-HSCs, and CMPs (Fig-
ures 7L–7N and S7P–S7R). Additionally, we incubated BM cells
from each group inMethoCult medium to assess the hematopoi-
etic output potential. Mice that received BM from the BCG-i.v.
group produced more colonies and mature CD11b-expressing
myeloid cells (as determined by flow cytometry) than mice that
received Mtb-i.v. BM (Figures 7O and 7P). Having determined
the impaired function of Mtb-exposed HSCs, we then sought
to elucidate the longevity of trained immunity. We derived
BMDMs from secondary engraftment mice and infected them
with Mtb in vitro. Remarkably, after two reconstitutions and
almost a year after the initial mycobacterium exposure, BMDMs
fromBCG-i.v. mice still provided significant protection fromMtb,
whereas BMDMs from Mtb-i.v. mice continued to exhibit
impaired control (Figure 7Q).
To examine the training program of BM-HSCs and progenitors
after secondary engraftment, we performed scRNA-seq on
HSCs and progenitor cells from animals that had originally
been exposed to BCG, Mtb, or PBS to evaluate whether there
were any transcriptional differences still present. After QC, we
kept a total of 7,959 LKS cell transcriptomes (3,872 PBS, 2,524
BCG, and 1,563 Mtb) and 9,859 transcriptomes from cKit+ cells
(3,353 PBS, 5,020 BCG, and 1,486 Mtb). These cells were clus-
tered in 7 and 8 groups in the LKS cell and progenitor popula-
tions, respectively (Figures S7S–S7U; see STAR Methods and
Figures S7V–S7X for details regarding LKS and progenitor clus-
tering inference and validation). In the LKS population, we
observed 2,684 and 2,230 DEGs between PBS and Mtb or
BCG in at least one of the cell clusters (Figure 7R; Tables S5
and S6). In progenitors, the effects of Mtb versus PBS (5,574
DEGs) appeared to bemuchmore pronounced than BCG versus
PBS (1,392 DEGs) (Figure 7S). Genes that respond significantly
to infection (FDR < 0.05 and abs(logFC) > 0.1 for BCG-PBS or
Mtb-PBS) show highly correlated treatment effects (Pearson
correlation averaged across clusters, r = 0.53 and 0.47 for LKS
cells and progenitor populations, respectively; p < 1E18 in all
clusters; Figure S7Y). Interestingly, among all cell clusters iden-
tified, the most committed MonPs (GMP_MonPs) showed the
most divergent response between BCG and Mtb, possibly ex-
plaining their remarkable differences in BMDM control of Mtb
growth (Figure 7Q). To further explore the pathways regulated
differentially in MonPs between the two groups, we performed
GSEA on the Mtb and BCG effects in this cluster. Focusing on
the hallmark list of gene sets (Liberzon et al., 2015), we detected
27 gene sets significantly enriched among DEGs between BCG-
i.v. or Mtb-i.v. and control conditions (Figure 7T; FDR < 0.01;
STAR Methods), with most pathways enriched uniquely under
BCG-i.v. or Mtb-i.v. conditions. To explicitly dissect the diver-
gence in the regulatory pathways altered by BCG-i.v. and
Mtb-i.v., for every MonP cell, we calculated the average gene
expression of all genes annotated in each of the sets analyzed.
We then compared differences in the overall activity of each of
the pathways betweenMonP cells derived from each group (Fig-
ure 7U). These analyses revealed that monocyte progenitors
from Mtb-i.v. mice present a phenotype that is characterized
by impaired inflammatory activity, as shown by the coordinated
decrease in the expression levels of genes associated with regu-
lation of inflammatory responses as well as IFN-I and IFN-II. In
contrast, genes involved in the E2F pathway, which is a critical
regulator of cell proliferation versus apoptosis (Polager and
Ginsberg, 2009), showed increased activity inmonocyte progen-
itors fromMtb-i.v. comparedwith BCG-i.v. mice. Consistent with
these findings, Gene Ontology enrichment analyses for the set of
DEGs between monocyte progenitors from BCG-i.v. and
Mtb-i.v. (1,707 under a more stringent cutoff: abs(logFC) > 0.2
and FDR < 0.01) revealed that genes upregulated in BCG-i.v.
compared with Mtb-i.v. were significantly enriched in terms
Figure 7. Mtb-i.v. Causes BM Exhaustion and Has Long-Term Effects on BMDM Training
(A) Mixed chimera model.
(B and C) Percentage of CD45.1+ versus CD45.2+ leukocytes (B) or Ly6Chi monocytes (C) in the blood (n = 5–10/group).
(D–J) In the BM, percentage of LKS cells (D), LT-HSCs (E), ST-HSCs (F), MPPs (G), CMPs (H), GMPs (I), and CLPs (J) after 16 weeks of reconstitution.
(K) Secondary engraftment model.
(L–N) Number of LKS cells (L), LT-HSCs (M), and CMPs (N).
(O and P) Myeloid colonies (O) and cell type by flow cytometry (P) by BM methylcellulose CFU assay.
(Q) In vitro BMDM CFUs.
(R and S) Number of genes up- and downregulated by Mtb and BCG in each cluster (abs(logFC) > 0.1 and FDR < 0.05) of LKS cells (R) and cKit+ cells (S).
(T) GSEA of genes ranked according to BCG (left) or Mtb (right) effects in the GMP_MonP cluster.
(U) Distribution of expression levels in GMP_MonP for gene set average markers in four different hallmark gene sets.
(V) Il6ra and Flt3 expression in the GMP_MonP cluster.
Two-way ANOVA followed by Sidak’smultiple comparisons test was used in (B), (C), (P), and (Q). One-way ANOVA followed by Tukey’s multiple comparisons test
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related to regulation of cytokine production, such as IFN-I (FDR =
1.5E4) or IL-6 (FDR = 2.6E5). In turn, genes more highly ex-
pressed in Mtb-i.v. than BCG-i.v. were enriched in functions
related to regulation of cell proliferation, such as mitotic nuclear
division (FDR = 2.1E23) as well as terms related to mitochon-
drial respiration, such as oxidative phosphorylation (FDR =
8.1E17), the ATP biosynthesis process (FDR = 2.9E8),
and the respiratory electron transport chain (FDR = 6.5E10)
(see Table S7 for the complete results). Key genes for regulation
of hematopoiesis (Flt3) and deployment of inflammatory re-
sponses (Il6ra) appear to be regulated divergently in Mtb versus
BCG (Figure 7V). Collectively, these results demonstrate that the
effect of BCG andMtb on the transcriptional profile of HSCs and
progenitors contributes to protective or failed trained immunity,
respectively, and lasts for at least 1 year.
DISCUSSION
One of the hallmarks of chronic infection is impaired immune-
driven resistance, allowing pathogen persistence (Altare et al.,
1998; Divangahi et al., 2008). Given that HSCs generate all
non-embryonically seeded immune cells, pathogen manipula-
tion of HSC responses will affect host defense to infection.
Although some mechanisms of rapid HSC adaptation to acute
infection (e.g., E. coli) have been studied, our understanding of
the HSC response to chronic infection, including Mtb, is
extremely limited. Interestingly, BM suppression in TB was
documented in the late 1980s (Hunt et al., 1987), and it has
been shown that Mtb persists in the BM by exploiting mesen-
chymal stem cells as a niche for its survival (Das et al., 2013).
However, the effect ofMtb on HSC function and the subsequent
immune response are incompletely understood. Here we
demonstrate thatMtb accesses the BM as early as 10 days after
pulmonary infection and reprograms HSCs at two critical levels:
(1) depleting myeloid progenitors and (2) impairing trained immu-
nity, both of which compromise host resistance to infection.
We recently showed how BCG and adjuvants like b-glucan
provide protective trained immunity againstMtb via HSC reprog-
ramming (Kaufmann et al., 2018; Moorlag et al., 2020). Although
there is a striking difference in the pathogenesis of BCG versus
Mtb (Figure 1B), with the exception of an early time point (day
7), the absolute numbers of HSC andMPP populations remained
similar. However, BCG andMtbwere highly dichotomous in their
modulation of lineage-restricted progenitors, where Mtb specif-
ically inhibited myelopoiesis. It was initially thought that specific
transcriptional networks of individual HSCs were the major de-
terminants for driving specific lineages (Kee, 2011; Novershtern
et al., 2011). However, similar to a recent study (Lauridsen et al.,
2018), we found that the transcriptional networks for myelopoie-
sis or lymphopoiesis were similar in HSCs/MPPs after BCG
vaccination or Mtb infection. Rather, the magnitude of several
key pathways, including IFN-I and heme/iron metabolism,
differed considerably. Both were implicated in lineage commit-
ment downstream of HSCs/MPPs because of the susceptibility
of myeloid but not lymphoid progenitors toMtb-induced necrop-
tosis, as has been shown similarly during shock-like Ehrlichia
infection (Smith et al., 2018). Additionally, we found that IFN-I
signaling alters mitochondrial Fe levels, disrupts MMP, and
drives necroptosis specifically in CMPs/GMPs. Our observation
that IFN-I was responsible for CLP expansion in poly (I:C) but not
Mtb is likely due to the fact that poly(I:C) specifically triggers
IFN-I production acutely, whereas Mtb chronically activates
many pathways that can promote lymphopoiesis independent
of IFN-I signaling.
Over 80% of available Fe in mammals exists in the form of
heme, and therefore pathogenic microorganisms likely evolved
to re-direct Fe as well as heme from their hosts (Soares and
Weiss, 2015). Fe plays a central role in TB pathogenesis because
it is required for growth ofMtb (Marcela Rodriguez andNeyrolles,
2014; Reddy et al., 2012). Indeed, mice lacking the heme-catab-
olizing enzyme heme oxygenase-1 (HO-1) are highly susceptible
to Mtb infection (Regev et al., 2012; Silva-Gomes et al., 2013).
The Fe generated via heme catabolism is primarily stored in its
inert ferric form by the protein ferritin (Gozzelino and
Soares, 2014). Similar to HO-1-deficient mice, we found that
BM-Fth/ mice showed a reduction of myelopoiesis at steady
state and were highly susceptible to Mtb infection. Although
we have not directly linked Fe metabolism to specific cell death
programs, the increased expression of RIPK3 in HSCs, the
involvement of necroptosis in BM failure (Rickard et al., 2014;
Roderick et al., 2014; Smith et al., 2018), the unique evolutionary
link betweenMtb and necroptosis (Behar et al., 2010; Divangahi
et al., 2009; Roca and Ramakrishnan, 2013; Zhao et al., 2017),
and the enhanced viability of Ripk3/ myeloid progenitors
followingMtb infection suggest that the IFN-I/iron axis biases he-
matopoiesis via necroptosis. Our results are also compatible
with an elegant study showing that, although tumor necrosis fac-
tor (TNF) promotes cell death in myeloid progenitors, it prevents
Table 1. Recapitulation of Number of Cells and Genes at the Different Stages of the Quality Control Process of the scRNA-Seq Data
Analyses
Mtb. Aerosol Challenge Serial Engraftment
LKS Progenitors LKS Progenitors
PBS Mtb PBS Mtb PBS BCG Mtb PBS BCG Mtb
Cells 3,305 6,580 3,741 8,259 5,391 4,673 2,786 5,094 8,987 11,994
Genes 31,053 31,053 31,053 31,053
Genes > 5 cells 16,071 15,103 17,019 16,268
Filtered cells 2,388 3,310 2,241 3,504 3,872 2,524 1,563 3,353 5,020 1,486
Filtered genes 15,550 14,568 16,480 15,676
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HSC necroptosis (Yamashita and Passegue, 2019). Therefore,
there are safeguard mechanisms in HSCs that are absent in
more committed myeloid progenitors.
Adjuvants such as b-glucan via IL-1 signaling (Moorlag et al.,
2020) or live vaccines like BCG via IFN-II (Kaufmann et al.,
2018) sustain myelopoiesis with protective imprinting to
generate trained immunity. However, Mtb limits myelopoiesis
and impairs trained immunity in an IFN-I-dependent manner.
Although the hematopoietic system rapidly adapts to stress to
meet the demand of the immune response, this on-demand
hematopoiesis is context specific with unique imprinting and
lineage fate decisions. For instance, IFN-I therapies are rarely
associated with BM suppression (Ioannou et al., 2010; Platanias
and Fish, 1999), indicating a that second stimulus is required to
cause BM failure. During LCMV infection, the suppressive
effects of IFN-I on hematopoiesis require IFN-II (de Bruin et al.,
2013). Given that the levels of IFN-II gene expression in HSCs
and progenitor cells are similar in BCG and Mtb infection, it is
tempting to speculate that duringMtb infection, IFN-I may over-
ride the protective effects of IFN-II in BCG-vaccinated mice so
that the relative magnitudes of these signals on HSCs determine
a protective versus detrimental response to infection.
One of the outstanding questions in the field of trained immu-
nity is the longevity of imprinting in trained immune cells. Using
a serial engraftment approach, we demonstrated that
imprinting of HSCs by BCG or Mtb lasts for at least a year
and is transmitted to macrophages. Additionally, our competi-
tive mixed chimera experiments indicate that BCG enhances
the capacity of HSC engraftment, an important consideration
for clinical management of TB and BM transplantation. Of
particular clinical interest is our observation that aerosolized
Mtb accesses the BM and reprograms HSCs similarly to the
systemic model of TB. While the majority of studies in mice
and humans have focused on the pulmonary response, our re-
sults show that Mtb disseminates from the lungs to the BM by
10 days post-infection. Although our transcriptomics data are
at 120 days post-infection, the early presence of Mtb suggests
that reprogramming may begin more rapidly, and future studies
should focus on discerning the kinetics of this imprinting in the
preclinical and clinical settings.
Limitations of Study
Although our study provides intriguing observations regarding
reprogramming of HSCs to generate protective or impaired
innate immunity against TB, at least three outstanding issues
remain:
(1) Genomics. Although we show that the longevity of myco-
bacterial imprinting lasts for at least 1 year, the mecha-
nisms of how HSCs are able to maintain these signatures
in the complete absence of mycobacteria for this lengthy
period of time are still unknown. Thus, studies investi-
gating the LT epigenetic landscape and transcriptomes
of HSCs versus BMDMs following mycobacterium expo-
sure are required to address this important question.
(2) Host-pathogen interaction.Our results indicate that theef-
fect of IFN-I on Fe metabolism could be a strategy forMtb
to obtain this essential element for its growth. However,
we know little about the genomic region (e.g., RD1) or viru-
lence factors ofMtb, which are responsible formodulating
the IFN-I/Fe axis in the BM. Why myeloid progenitors, but
not HSCsor lymphoid progenitors, are prone to death dur-
ingMtb infection and how exactly Fe metabolism is linked
to necroptosis also remain to be determined.
(3) TB pathogenesis. BecauseMtb biases HSCs toward lym-
phopoiesis, it may also intrinsically reprogram lymphoid
lineages to generate ineffective lymphocytes against TB.
Although this was not explored in our study, it may explain
why there is no natural immunity to TB and the lack of as-
sociation between increased conventional T cell re-
sponses and protection against Mtb (Barber et al., 2011;
Nemes et al., 2018; Tameris et al., 2013; Tzelepis et al.,
2018). This type of immune subversion is conceptually
similar to the observation that human T cell epitopes of
Mtb are evolutionarily hyperconserved (Comas et al.,
2010) and the paradoxical notion that T cells may actually
contribute to TB transmission by participating in induction
of cavitary lung disease (Genewein et al., 1993; Rodrigo
et al., 1997). Certainly, future studies investigating the po-
tential effect of Mtb on lymphopoiesis are required to
carefully test this hypothesis.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Fixable Viability Stain eFluor501 eBioscience Cat#65-0863-18
anti-CD16/32 (clone 93) eBioscience RRID: AB_467134
anti-Ter-119 biotin-conjugated (clone
Ter119)
BD Bioscience RRID: AB_394985
anti-CD11b biotin-conjugated (clone
M1/70)
BD Bioscience RRID: AB_394773
anti-CD5 biotin-conjugated (clone 53-7.3) BD Bioscience RRID: AB_394557
anti-CD4 biotin-conjugated (clone RM4-5) BD Bioscience RRID: AB_394581
anti-CD8a biotin-conjugated (clone 53-6.7) BD Bioscience RRID: AB_394567
anti-CD45R biotin-conjugated (clone
RA3-6B2)
BD Bioscience RRID: AB_394616
anti-Ly6G/C biotin-conjugated (clone
RB6-8C5)
BD Bioscience RRID: AB_394641
Streptavidin – APC-Cy7 eBioscience RRID: AB_10366688
Streptavidin - BUV395 BD Bioscience Cat# 564176
anti-c-Kit – APC (clone 2B8) eBioscience RRID: AB_469430
Anti-cKit-BV421 (clone 2B8) BD Bioscience RRID: AB_2739664
anti-Sca-1 – PE-Cy7 (clone D7) eBioscience RRID: AB_469668
anti-CD150 – eFluor450 (clone mShad150) eBioscience RRID: AB_2574045
anti-CD48 – PerCP-eFluor710 (clone
HM48-1)
BD Bioscience RRID: AB_396724
anti-Flt3 – PE (clone A2F10.1) BD Bioscience RRID: AB_395079
anti-CD34 – FITC (clone RAM34) eBioscience RRID: AB_465020
Anti-CD16/32-PerCP efluor 710 (clone 93) eBioscience RRID: AB_996659
Anti-CD115 - BV711 (clone AFS98) Biolegend RRID: AB_2562679
anti-F4/80 – APC-Cy7 (clone BM8) eBioscience RRID: AB_469452
Anti-F480-APC (clone BM8) eBioscience RRID: AB_2784647
anti-Ly6C – APC (clone HK1.4) eBioscience RRID: AB_1724155
anti-Ly6C – FITC (clone AL-21) BD Bioscience RRID: AB_394628
Anti-Ly6C – APC (clone HK1.4) eBioscience RRID: AB_1724153
anti-Ly6G – PerCP-eFluor710 (clone
1A8-Ly6g)
eBioscience RRID: AB_2573892
anti-Siglec F – PE-CF594 (clone E50-2440) BD Bioscience RRID: AB_2687994
anti-CD11c – PE-Cy7 (clone HL3) BD Bioscience RRID: AB_2033997
anti-CD11b – eFluor 450 (clone M1/70) BD Bioscience RRID: AB_1582236
anti-NK1.1 – BV650 (clone PK136) BD Bioscience Cat#564143
anti-CD19 – PE-Cy7 (clone 1D3) eBioscience RRID: AB_657664
anti-CD3 – PE (clone 145-2C11) BD Bioscience RRID: AB_465496
anti-CD4 – FITC (clone GK1.5) eBioscience RRID: AB_464892)
anti-CD4 - eFluor 450 (clone GK1.5) eBioscience RRID: AB_10718983
anti-CD8 – AlexaFluor 700 (clone 53-6.7) BD Bioscience RRID: AB_396959
anti-CD127 – BV786 (clone SB/199) BD Bioscience RRID: AB_2738403
Anti CD127 - BV605 (clone A7R34) Biolegend RRID: AB_2562114
anti-Ly6G – AlexaFluor700 (clone RB6-8C5) eBioscience RRID: AB_10611860
(Continued on next page)
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Continued
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anti-CD45.1 – APC (clone A20) BD Bioscience RRID: AB_1645214
anti-CD45.2 – BUV395 (clone 104) BD Bioscience Cat# 564616
anti-FTH Cell Signaling Technology RRID: AB_11217441
anti-CD71-eFluor 450 (clone R17217) eBioscience RRID: AB_2574027)









MitoTracker Green FM ThermoFischer Scientific Cat#M7514
MitoTracker Orange CMTMRos ThermoFischer Scientific Cat#M7510
MitoSOX Red ThermoFischer Scientific Cat# M36008
Viability NucSpot Far-Red Biotium Cat#40085
PE Annexin V Apoptosis Detection Kit with
7-AAD
BioLegend Cat# 640934
FOXP3 Transcription Factor Staining Kit eBioscience Cat# 00-5523-00
B16-Blue IFN-a/b Cells Invivogen Cat# bb-ifnt1
Bacterial and Virus Strains
Mycobacterium bovis BCG-TICE
(TMC 1028)
ATCC ATCC Number: 35743
Mycobacterium tuberculosis H37Rv
(TMC 102)
ATCC ATCC Number: 27294
Mycobacterium bovis BCG-GFP Dr. Marcel Behr, McGill University, Montreal Alter et al., 2010
Mycobacterium tuberculosis H37Rv-GFP Dr. Marcel Behr, McGill University, Montreal This Paper
Mycobacterium tuberculosis H37Rv-DRD1 Dr. Marcel Behr, McGill University, Montreal Lewis et al., 2003
Chemicals, Peptides, and Recombinant Proteins
Poly (I:C) (LMW) Invivogen Cat#tlrl-picw
b-Glucan Sigma-Aldrich Cat#G5011
Isoniazid Sigma-Aldrich Cat#13377-150G
Rifampicin EMD Millipore Cat#557303-5GM
Enrofloxacin, Baytril 50mg/ml Bayer DIN 02169428
RPMI-1640 with L-glutamine Wisent Cat#350-000CL
Middlebrook 7H9 broth Fischer Scientific Cat#CDF0713-17-9
Middlebrook 7H10 Agar Fischer Scientific Cat#DF0627-17-4
Glycerol for ADC Wisent Cat#800-0400-LL
BSA for ADC Wisent Cat#800-195-EG
Dextrose for ADC Fisher Scientific Cat#D16-10 CAS Number 50-99-7
NaCl for ADC Fischer Scientific Cat#S6713
Oleic acids for OADC Sigma Cat#364525
Tween 80 Fischer Scientific Cat#338-500 CAS Number 9005-65-6
FBS Wisent Cat#80150
HEPES Wisent Cat#330-050-EL
Non-Essential Amino acids Wisent Cat#321-010-EL
Essential Amino acids Wisent Cat#321-011-EL
Sodium Pyruvate Wisent Cat#600-110-EL
Penicillin/Streptomycin Wisent Cat#450-115-EL
(Continued on next page)
ll
OPEN ACCESS
e2 Cell 183, 752–770.e1–e11, October 29, 2020
Article
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Corning Cell Stripper Fischer Scientific Cat#MT25056Cl
Collagenase IV Sigma Cat#C5138
Paraformaldehyde 1% Thermo Fischer Cat#28908
Kanamycin Wisent Cat#400-145-1G
QIAzol Lysis Reagent QIAGEN Cat#79306
RT Mastermix Diamed Cat#ABMG490
Abm EvaGreen Diamed Cat#ABMMastermix-S
PANTA Fischer Scientific Cat#B4345114
Critical Commercial Assays
Magmax-96 Total RNA Isolation Kit ThermoFischer Cat#AM1830
SignalFire ECL Reagent Cell Signaling Technologies Cat#6883
Tamoxifen Sigma-Aldrich Cat #T5648
Deposited Data
Bulk RNA-Seq, Single cell RNA-Seq Gene expression ómnibus (GEO) database GSE156137
Experimental Models: Cell Lines
L929 cell line ATCC ATCC Number: CCL-1
B16-Blue IFN-a/b Cells InvivoGen Cat#bb-ifnt1
Experimental Models: Organisms/Strains
Mouse:C57BL/6J The Jackson Laboratory IMSR Cat# JAX:000664,
RRID: IMSR_JAX:000664
Mouse: Ifnar 1/ The Jackson Laboratory IMSR Cat# JAX:028288
Mouse: B6.129S7-Ifngr1tm1Agt/J The Jackson Laboratory IMSR Cat# JAX:003288,
RRID: IMSR_JAX:003288
Mouse CD45.1+ B6. SJL-Ptprca
Pepcb/BoyJ
The Jackson Laboratory IMSR cat# JAX:002014,
RRID: IMSR_JAX:002014
Mouse: Rosa26CreERT2Fthlox/lox Dr. MP Soares (Instituto Gulbenkian
Ciencia, Portugal)
(Blankenhaus et al., 2019)
Mouse: Ripk3/ Dr. Vishva Dixit (Genentech,
San Francisco)
(Newton et al., 2014)
Mouse: NOD.129S7(B6)-Rag1tm1Mom/J The Jackson Laboratory IMSR Cat# JAX:003729,
PRID: IMSR_JAX003729
Software and Algorithms
Graph Pad Prism, version 6.0c http://www.graphpad.com/scientific-
software/prism/
SCR_015807
FACSDiva Software BD Biosciences SCR_001456
FlowJo software v.10.1 Tree Star SCR_000410
Amnis INSPIRE software Luminex https://www.luminexcorp.com/
imaging-flow-cytometry/
Amnis IDEAS software Luminex https://www.luminexcorp.com/
imaging-flow-cytometry/
Trim Galore (version 0.2.7) Krueger, n.d. http://www.bioinformatics.babraham.ac.
uk/projects/trim_galore/
edgeR Robinson et al., 2010 SCR_012802
limma Ritchie et al., 2015 SCR_010943
CLUEGO Bindea et al., 2009 SCR_005748
kallisto (v0.43.0) Bray et al., 2016
Seurat Satija et al., 2015 SCR_007322
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Maziar
Divangahi (maziar.divangahi@mcgill.ca).
Materials Availability
No unique reagents were generated for this study.
Data and Code Availability
All data generated in this study (bulk and single cell RNA-Seq) are available in GEO database under the accession number
GEO: GSE156137. All the Software packages and methods used in this study have been properly detailed and referenced under
‘‘Quantification and Statistical Analysis.’’
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Six- to ten-week old CD45.1 and CD45.2 C57BL/6J, Ifnar1/, and Ripk3/ (kindly provided by Dr. Vishva Dixit, Genentech) mice
were housed and bred at the RI-MUHC,Montreal, QC, Canada. Rosa26CreERT2Fthlox/lox mice were provided byMPSoares (Portugal)
and tamoxifen treatment was performed as previously described (Blankenhaus et al., 2019). All animal studies were conducted in
accordance with the guidelines of, and approved by, the Animal Research Ethics Board of McGill University (project ID: 5860).
Mice were housed under SPF conditions with ad libitum access to food and water. Experiments were conducted using male and fe-
male sex- and age-matched mice that were randomly assigned to experimental groups.
METHOD DETAILS
Bacterial culture
Mtb H37Rv, Mtb H37Rv DRD1 (Lewis et al., 2003) and BCG-TICE were grown in 7H9 broth (BD) supplemented with 0.2% glycerol
(Wisent), 0.05% Tween80 (Fisher), and 10% albumin-dextrose-catalase (ADC) under constant shaking at 37C. For experiments
involving Mtb-GFP and BCG-GFP, bacteria were grown as above with the addition of kanamycin (25mg/mL; Wisent) for selection
of resistant bacteria. For in vitro and in vivo experiments,Mtb (H37Rv) bacteria in log growing phase (OD 0.4 – 0.9) were centrifuged
(4000 RPM, 15 minutes) and resuspended in RPMI without penicillin/streptomycin or sterile PBS. Single cell suspensions were
obtained by passing the bacteria 10-15 times through a 22G needle (Terumo).
In vivo experiments
Mtb infection or BCG vaccination of mice
Throughout the study, mice were intravenously (iv) infected withMtbH37Rv,MtbH37Rv-DRD-1 or vaccinated with BCG-TICE with a
dose of 1x106 single-suspended bacteria in 100ml PBS, unless otherwise indicated. For aerosol infection, mice were infected with
approx. 50-100 CFU of Mtb H37Rv in a nose-only aerosol exposure unit (Intox). Infection dose was confirmed by enumerating the
lung CFU one-day after infection.
Antibiotic treatment of mice
For antibiotic treatment with antimycobacterial drugs, the drinking water of the mice was supplied with 100mg/L Isoniazid (INH;
Sigma-Aldrich) and 100mg/L Rifampicin (RIF; Fisher) for four weeks. The antibiotic treatment was followed by a two-week wash-
out period on regular water.
Poly (I:C) and b-Glucan treatment
C57BL/6J and Ifnar1/mice were treated with Poly (I:C) (Invivogen) (200mg/mouse) intraperitoneally (i.p.) at day 0, 2, 4, 6. Mice were
sacrificed at day 3 and day 7 depending on the experiment. For b-glucan (Sigma, catalog #G5011), mice were treated with 1mg/
mouse i.p. at day 0 and day 3. Mice were sacrificed at day 7.
Adoptive transfer experiment
C57BL/6J mice were vaccinated with BCG-iv or infected with Mtb-iv (1x106 CFU) or PBS injected (PBS-iv). After 4 weeks, BM cells
were harvested and differentiated into BMDMs in the presence of anti-TB drugs to kill any residualMtb. BMDMs were infected with
H37Rv (MOI of 0.2) for 30 minutes at 37C and 5%CO2 with frequent agitation. Free bacteria were then removed by washing 5x with
cold RPMI, each followed by centrifugation (1500 RPMI) for 10 min at 4C. BMDMs (0.5x106 cells) were resuspended in 40 mL PBS
and then intratracheally transferred into naiveRag1/mice (Divangahi et al., 2009, 2010). The initial number of bacteria prior to trans-
fer was assessed by plating Mtb-infected macrophages on 7H10 agar plates.
Competitive Mixed chimeric mouse model
C57BL/6J mice were either PBS-injected or BCG iv-vaccinated or Mtb iv-infected (1x106 bacteria). After four weeks, mice were
treated with anti-TB drugs for four weeks. The antibiotic treatment was followed by a two-week wash-out period on regular water.
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BM cells (2x105/group) from various pairs of either BCG iv-vaccinated, Mtb-iv infected or PBS controls were admixed and intrave-
nously injected into CD45.1+ recipient C57BL/6Jmice 16 hours post lethal irradiation with 9Gy.Micewere kept under antibiotic treat-
ment (0.5g Enrofloxacin (Bayer) per liter of drinking water) for three days before and two weeks after irradiation along with anti-TB
drugs for 5 days. Engraftment was measured after 4, 8, 12 and 16 weeks of reconstitution by staining peripheral blood cells.
Secondary engraftment mouse model
C57BL/6J mice were either PBS-injected or BCG iv-vaccinated or Mtb iv-infected (1x106 bacteria). After four weeks, mice were
treated with anti-TB drugs for four weeks. The antibiotic treatment was followed by a two-week wash-out period on regular water.
CD45.2+ BM cells (4x106) either from BCG iv-vaccinated orMtb iv-infected mice were intravenously injected into congenic CD45.1+
C57BL/6J mice 16 hours post lethal irradiation with 9 Gy. CD3+ T cells were depleted from the BM by MACS sorting prior to trans-
plantation. Mice were kept under antibiotic treatment (0.5g Enrofloxacin (Bayer) per liter of drinking water) for three days before and
two weeks after irradiation, along with anti-TB drugs for 5 days. The chimerismwas validated after 16 weeks of reconstitution by flow
cytometry and was > 96%. For second engraftment, CD45.2+ BM cells (4x106) from 16 weeks reconstituted mice were intravenously
injected into CD45.1+ C57BL/6J mice 16 hours post irradiation with 9 Gy. The chimerism was validated after 16 weeks of reconsti-
tution by flow cytometry and was > 96% and subsequent experimentation was performed.
Generation of chimeric mice using inducible Tamoxifen model
CD45.1+ B6mice were lethally irradiated with 9 Gy following 3 days of antibiotic treatment (0.5g Enrofloxacin (Bayer) per liter of drink-
ing water). 16 hours later, the BM compartment was reconstituted with 4x106 nucleated cells from Rosa26CreERT2Fthlox/lox mice
(CD45.2+) and antibiotic treatment was maintained for 2 additional weeks. Between 8-12 weeks post-injection, reconstitution was
validated by flow cytometry and was > 90%. Tamoxifen was administered at 50mg/kg (10% ethanol in corn oil v/v) i.p. for 5 consec-
utive days and the mice were then rested for 1 week.
In vitro experiments
Generation of BMDM
BM from both femurs and tibiae was harvested in RPMI (Wisent) supplemented with 10% heat-inactivated FBS (Wisent). Cells were
subsequently seeded in 7ml RPMI supplemented with 2mM L-glutamine, 10% FBS, 2% HEPES, 1% non-essential amino acids, 1%
essential amino acids, 0.14% 5N NaOH, 1mM sodium pyruvate, 100U/ml penicillin, 100mg/ml streptomycin (all Wisent), 30% of
L929-conditioned media (LCM) and isoniazid (INH 5mg/ml) in Petri dishes. After 3 days of incubation at 37Cwith 5% CO2, fresh me-
dium containing LCMand INH (5mg/ml) was added. Cells were allowed to differentiate intomacrophages for a total of 6 days and then
were harvested by removing the supernatant and addition of 4ml cell stripper (Corning) for 20 minutes at 37C. As evaluated by flow
cytometry, the purity was > 95%. INH was added only during the differentiation of the BMDM derived from BM cells of non-treated
BCG-iv orMtb-iv infected mice. Yield was determined by trypan blue dead cell exclusion counts and normalized to PBS control mice
yields. For all experiments equal number of macrophages were seeded.
Macrophage Infection
BMDMs (1x106 cells) were seeded in 6-well plates supplemented with RPMI without penicillin/streptomycin (1 ml) and incubated
overnight at 37C with 5% CO2. The next day, cells were infected with Mtb H37Rv (MOI 1), or BCG (MOI 10) unless otherwise indi-
cated. Cells were incubated for 4 hours at 37C with 5% CO2. Subsequently, cells were washed 3x with sterile PBS and were then
incubated in supplemented RPMI without penicillin/streptomycin. CFUs were enumerated at 4 hours, day 3 and day 5 post-infection.
Mycobacterial CFU Enumeration
For CFU enumeration in in vitro infected cells, cells were lysed with 500ml sterile H2O for five minutes, followed by addition of 500ml
PBS supplemented with 0.05% Tween80. For CFU enumeration in tissues, organs were homogenized in 1ml 7H9 broth (BD) supple-
mented with 0.2% glycerol (Wisent), 0.05% Tween80 (Fisher), and 10% ADC using OmniTip Plastic Homogenizer Probes (Omni In-
ternational). Serial dilutions in PBS+0.05% Tween80 were plated on 7H10 agar plates with 10%OADC enrichment and PANTA (BD).
Plates were then incubated at 37C and counted after 21 days.
Western Blot
BM cells from BM Fth/ or BM Fth+/+ were isolated. Briefly, cells were lysed in lysis buffer (1% Triton X-100, 150mM NaCl, 20mM
HEPESpH7.5, 10%glycerol, 1mMEDTA, supplementedwith anti-protease and anti-phosphatase cocktails, Roche) and protein con-
centration was determined using BCA assay (Pierce). 20 mg of protein was resolved by SDS-PAGE and transferred onto PVDFmem-
branes (Biorad). Membranes were blocked and incubated overnight at 4C with gentle agitation with anti-Fth (1:1000, Cell Signaling
Technologies) or actin (1:10 000, Sigma-Adrich). Then primary antibodies were conjugated to secondary HRP-conjugated antibodies
and the signal was detected using Clarity ECL kit (Biorad) and acquired on Chemidoc MP System (Biorad).
Methylcellulose assay
5x103 BM cells were suspended in methocult medium (MethoCult GFM3534; StemCell Technologies) with specific cytokines to pro-
mote the growth of myeloid progenitors. Colonies were counted after 10-12 days. Cells were collected by washing with PBS and
stained for CD11b and cKit.
Quantification of IFN-I
Secretion of total active IFN-I (both IFN-a and IFN-b) in BM supernatants was assessed using B16-blue IFNa/b reporter cell line
(InvivoGen), according to the specifications of the manufacturer.
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Flow Cytometry
BM/Spleen cells (33 106 cells) after RBC lysis were stained with fixable viability dye eFluor501 (eBioscience) at the concentration of
1:1000 for 30 minutes (4C). Subsequently, the cells were washed with PBS supplemented with 0.5% BSA (Wisent) and incubated
with anti-CD16/32 (clone 93, eBioscience) at a concentration of 1:100 in PBS/0.5% BSA at 4C for 10 minutes except for myeloid
progenitor and downstream progenitors staining. The following antibodies were then used for staining: anti-Ter-119 (clone
Ter119), anti-CD11b (clone M1/70), anti-CD5 (clone 53-7.3), anti-CD4 (clone RM4-5), anti-CD8a (clone 53-6.7), anti-CD45R (clone
RA3-6B2), and anti-Ly6G/C (clone RB6-8C5) all were biotin-conjugated (all BD Bioscience) and added at a concentration of 1:100
for 30 minutes at 4C. Cells were subsequently washed with PBS/0.5% BSA. For staining of LKS, HSCs, and MPPs: Streptavi-
din–APC-Cy7 (eBioscience), anti-c-Kit–APC (clone 2B8, eBioscience), anti-Sca-1–PE-Cy7 (clone D7, eBioscience), anti-CD150–
eFluor450 (clone mShad150, eBioscience), anti-CD48–PerCP-eFluor710 (clone HM48-1, BD Bioscience), anti-Flt3–PE
(clone A2F10.1, BD Bioscience), and anti-CD34–FITC (clone RAM34, eBioscience) (all 1:100) were added and incubated at 4C
for 30 minutes. For staining of myeloid and lymphoid progenitors: Streptavidin–APC-Cy7 (eBioscience), anti-c-Kit–APC (clone
2B8, eBioscience), anti-Sca-1–PE-Cy7 (clone D7, eBioscience), anti-CD34–FITC (clone RAM34, eBioscience), anti-CD16/32
PerCP-eFluor710 (clone 93, eBioscience) and anti-CD127 BV786 (clone SB/199, BD bioscience) or anti CD127-BV605 (clone
A7R34, Biolegend) (all 1:100) were added and incubated at 4C for 30 minutes. For cMoPs and downstream progenitors: BM cells
were incubated with biotin antibodies against lineage markers as mentioned above, except we included anti-Ly6G (clone 1A8-Ly6G)
replacing anti-Ly6C/6G at 4C for 30 minutes. Cells were subsequently washed with PBS/0.5% BSA. Following antibodies were
added: Streptavidin–BUV-395(BD Bioscience), anti-c-Kit–Pacific Blue (clone 2B8, BD Bioscience), anti-Sca-1–PE-Cy7 (clone D7,
eBioscience), anti-CD34–FITC (clone RAM34, eBioscience), anti-CD16/32–PerCP-efluor710 (clone 93, eBioscience), anti-CD115
BV711 (clone AFS98, BioLegend), anti-Flt3–PE (clone A2F10.1, BD Bioscience), anti-Ly6C–APC (clone HK1.4, eBioscience) and
anti-Ly6G AF700 (clone 1A8–Ly6G, eBioscience) all (1:100 except Streptavidin BUV395 at 1:50) were added and incubated at
4C for 30 minutes. In some experiments cells were further stained with AnnexinV–PE and 7AAD (Biolegend) or NucSpot Far-Red
(Biotium), according to the manufacturer’s instructions and unfixed cells were acquired immediately. In another set of experiments,
cells were fixed and permeabilized using the FOXP3 Transcription Factor Staining Kit (eBioscience) for 1 hour at 4C. Then, cells were
stained with anti-Ki67–PE (clone 16A8, BioLegend) (1:400) for 1 hour at 4C and acquired.
Staining for innate and adaptive immune cells
Red blood cells were lysed in bonemarrow and collagenase IV (Sigma)-treated lung samples. Lung, spleen or BM cells (33 106) were
then stained with fixable viability dye eFluor501 (eBioscience) at the concentration of 1:1 000 for 30 minutes (4C). Subsequently, the
cells were washed with PBS supplemented with 0.5% BSA (Wisent) and incubated with anti-CD16/32 (clone 93, eBioscience) at a
concentration of 1:100 in PBS/0.5% BSA at 4C for 10. After washing, cells were incubated with fluorochrome tagged antibodies
at 4C for 30 minutes. Antibodies for the innate panel: anti-CD11b–Pacific Blue (clone M1/70, eBioscience), anti-CD11c–PE-Cy7
(clone HL3, BD Bioscience), Siglec-F–PE-CF594 (clone E50–2440, BD Bioscience), F4/80–APC (clone BM8, eBioscience),
Ly6C–FITC (clone AL-21, BD Bioscience), Ly6G–PerCP-eFluor710 (clone 1A8, eBioscience). Antibodies for the adaptive panel:
anti-CD3–PE (clone 145-2C11, eBioscience), anti-CD19–PE-Cy7 (clone eBio1D3 (1D3), eBioscience), anti-CD4–eFluor450 or anti-
CD4-FITC (clone GK1.5, eBioscience), anti-CD8–AF700 (clone 53-6.7, BD Bioscience). All cells were subsequently washed with
PBS/0.5% BSA and resuspended in 1% paraformaldehyde.
Blood Leukocytes
50 mL of whole blood collected in heparin tubes (BD) was incubated with fluorochrome tagged antibodies at 4C for 30 minutes. An-
tibodies for the innate panel: anti-CD11b–Pacific Blue (clone M1/70, eBioscience), anti-CD11c–PE-Cy7 (clone HL3, BD Bioscience),
anti-Siglec-F–PE-CF594 (clone E50–2440, BD Biosciences), anti-F4/80–APC (clone BM8, eBioscience), anti-Ly6C–FITC (clone AL-
21, BD Bioscience), anti-Ly6G–PerCP–eFluor710 (clone 1A8, eBioscience). Antibodies for the adaptive panel: anti-CD3–PE
(clone145-2C11, eBioscience), anti-CD19–PE-Cy7 (clone eBio1D3 (1D3), eBioscience), anti-CD4–FITC (clone GK1.5, eBioscience),
anti-CD8 AF700 (clone 53-6.7, BD Bioscience). After RBC lysis, cells were subsequently washed with PBS/0.5% BSA and resus-
pended in 1% paraformaldehyde.
If required, panels were modified to contain anti-CD45.1–APC (clone A20, BD Bioscience, 1:100) and anti-CD45.2–BUV395 (clone
104, BD Bioscience, 1:100).
Cells were acquired on the Fortessa-X20 (BD) and analyzed using FlowJo software (version 10.6.1). All percentages are of single
viable frequency, unless otherwise indicated.
Evaluation of Mitochondrial Fe2+, Mitotracker Green/Orange and Mitosox Red
BM mononuclear cells were stained with rhodamine B 4-[(1,10-phenanthrolin-5-yl)aminocarbonyl]benzyl ester (RPA) (Squarix) at
0.2 mM, or Mitotracker Green and Orange 150n5M, or MitoSox Red 1mM (all from Invitrogen technologies) in PBS for 30 min at
room temperature and then washed with PBS. The dye-loaded cells were further stained with antibodies for progenitors as
mentioned above. RPA MFI fluorescence was normalized to PBS groups, inversed and multiplied by 100 to give a percentage of
iron pools compared to PBS, as fluorescence is quenched by higher levels of iron. For experiments involving mitochondrial potential,
dysregulated mitochondria were considered as Mitotracker Greenhi and Mitotracker Orangelo as previously described
(Ip et al., 2017).
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ImageStream
Freshly isolated BMcells from naive C57BL/6Jmicewere infectedwithMtb-GFP or BCG-GFP (MOI 3) for 4 hours. BMcells were then
stainedwith antibodies for LKS and Lineage+ cells. Imageswere captured on an Amnis ImageStreamMark II Imaging FlowCytometer
with 40Xmagnification (EMDMillipore). Data were acquired and analyzed using Amnis INSPIRE software and Amnis IDEAS software,
respectively. ImageStream samples were also acquired using Fortessa-X20 (BD) and then analyzed using FlowJo software.
Cell Sorting
For stem cell sorting, BM cells were harvested from femurs, tibiae, humeri and ilia, and incubated with the described biotin-con-
jugated antibodies against lineage-committed cells. Subsequently, the cells were incubated with MACS streptavidin conjugated
microbeads (Miltenyi) for 30 minutes at 4C. A depletion of the lineage-committed cells was performed using MACS magnets
with LS Columns (Miltenyi, #130-042-401). The remaining cells were incubated with the above described antibodies for LKS/
HSCs/MPPs. DAPI (0.005mg) was added for viability staining to 10x106 cells right before sorting on a BD FACSAria Fusion sorter.
Cells were sorted in 200ml lysis buffer of Magmax-96 Total RNA Isolation Kit (life technologies, Ambion 1830) at room temperature
or in PBS containing 0.04% BSA for single cell sequencing. RNA samples were vortexed for 30 s, and subsequently stored at
–80C until RNA extraction.
Perls’ Prussian blue iron staining
Bone epiphyses were removed and femurs were fixed in 4% PFA for 24-48h followed by washing with PBS. Perls’ staining was per-
formed by Histopathology Core of RI-MUHC, Montreal, QC, Canada.
Bulk RNA-seq library preparation and sequencing
Total RNA was extracted from the sorted HSCs and MPPs using Magmax-96 Total RNA isolation kit (life technologies, Ambion
1830M). RNA quality was evaluated spectrophotometrically, and quality was assessed with the Agilent 2100 Bioanalyzer (Agilent
Technologies). All samples showedRNA integrity number > 8. RNA-sequencing libraries were prepared using the SMARTer Stranded
RNA-Seq Kit (Clontech). Once prepared, indexed cDNA libraries were pooled in equimolar amounts andwere sequencedwith single-
end 100 bp reads on an Illumina HiSeq2500.
Single cell RNA-seq library preparation and sequencing
Single cell transcriptomic data was collected for LKS (Lin- Sca-1+ cKit+) and myeloid progenitor (Lin- Sca-1- cKit+) populations in the
context of theMtb aerosol challenge and the second engraftment experiments. Cells were sorted as described above into PBS con-
taining 0.04% BSA.
Single-cell GEMs were generated using a Chromium Controller instrument (10x Genomics). Sequencing libraries were prepared
using Chromium Single Cell 30 Reagent Kits (10x Genomics), according to the manufacturer’s instructions. Briefly, GEM-RT was per-
formed in a thermal cycler: 53C for 45 min, 85C for 5 min. cDNA was cleaned up with DynaBeads MyOne Silane Beads (Thermo-
Fisher Scientific) and amplifiedwith a thermal cycler: 98C for 3min, cycled 123 98C for 15 s, 67C for 20 s, 72C for 1min, and 72C
1 min. After a cleanup with SPRIselect Reagent Kit, the libraries were constructed by performing the following steps: fragmentation,
end-repair, A-tailing, SPRIselect cleanup, adaptor ligation, SPRIselect cleanup, sample index PCR, and SPRIselect size selection.
Libraries were sequenced on a NovaSeq S2 flowcell with 100 bp paired-end reads.
QUANTIFICATION AND STATISTICAL ANALYSES
Statistics for mouse work
Statistical analyses were performed using Graph Pad Prism, version 8. Data are displayed as mean ± SEM. Each symbol represents
an individual mouse, or an individual n value is listed in the figure legends. Statistical significance was determined by t test, one-way
ANOVA, two-way ANOVA, or log-rank test as indicated in the figure legends, and significance is represented by the following
scheme: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Bulk RNA-seq
RNA-seq Analyses: Pre-processing Steps
Experimental mice were split into three treatment groups, (either BCG-iv,Mtb-iv or the control: PBS-iv) with 4 animals each. 28 days
after treatment, animals were sacrificed, and their BM extracted. Hematopoietic stem cells (HSCs; Lin- cKit+ Sca-1+ CD150+) and
multipotent progenitors (MPPs; Lin- cKit+ Sca-1+ CD150-) were sorted as described above. RNAwas then extracted and sequenced,
generating a dataset of 23 samples (two cell typesmultiplied by three treatments and by four animals per group, minus one HSC-PBS
sample that did not produce a valid RNA library).
As for RNA-seq data pre-processing, low-quality score bases (Phred score < 20) and adaptor sequences were trimmed using
Trim Galore (version 0.2.7) (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Mapping of the resulting reads to
the mouse genome reference sequence (Ensembl GRCm38 release 81) was done with kallisto (v0.43.0) (Bray et al., 2016). Then,
protein coding genes were selected, and samples were normalized using the weighted trimmed mean of M-values algorithm
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(TMM), implemented in edgeR (Robinson et al., 2010). Data were log-transformed using voom, within the limma package (Ritchie
et al., 2015) and lowly-expressed genes were filtered out, defined as those with a median log2-transformed expression lower
than 2 within all experimental groups (i.e., treatment-cell-type combinations). This produced a reads matrix of 12132 genes.
Differential expression analyses
The filtered matrix was then re-normalized, using EdgeR and voom, and modeled according to the following design, using limma
(Ritchie et al., 2015):
ExpressionCell_type+Treatment:cell_type
From thementionedmodel design run over all 12132 genes in the dataset, BCG andMtb effects were retrievedwithin each cell type
(Table S1, Tabs i-iv). Focus was then put on genes showing treatment responses in any cell-type (2214 genes responding at 1% FDR
to either BCG orMtb at HSCs; 3542 for MPPs) and these genes were then tested for differences in expression between the two treat-
ments (Table S1, tabs v-vi). Differences in expression between HSCs and MPPs were also characterized (Table S1, tabs vii-ix). We
found 581, 608 and 600 differentially expressed genes between the HSCs andMPPs, at 1%FDR, in cells coming fromPBS, BCG and
Mtb treated mice, respectively.
scRNA-seq
scRNA-seq data pre-processing and quality control
Sample preprocessing was done using the count command of CellRanger (Zheng et al., 2017) against the mm10 1.2.0 reference
genome, yielding numbers of cells between 3,305 and 11,994 depending on experiment, cell population and condition (Table 1,
row 1). Initially, we measured the expression of 31053 genes in each cell (Table 1, row 2). In each of the four datasets analyzed,
we excluded lowly expressed genes, detected in less than 5 cells in all conditions, in order to select a relevant gene set in each exper-
iment to conduct quality control on (Table 1, row 3). Using this reference gene set in each experiment, we determined the percentage
of protein coding genes detected, as well as the percentage of mitochondrial RNA in each cell. We then excluded cells that featured:
(i) a high fraction of mitochondrial RNA reads (fmito > 5%), (ii) a low percentage of protein-coding genes (fpc < 95%) or (iii) a number of
UMIs that was either too low (< nUMI < 5000) or too high (nUMI > 40;000). After the filtering, we kept variable numbers of cells per exper-
iment and condition, comprised between 578 and 4733 (Table 1, row 4). Using this final set of cells, we filtered out genes detected in
less than five cells in all conditions and re-normalized the percentages of protein coding genes and mitochondrial transcripts per cell
on the final dataset. At the end, the number of genes included for clustering and differential expression analyses varied between
14568 and 16480, depending on the experiment and cell population (Table 1, row 5).
scRNA-seq data normalization
We used the function computeSumFactors, from the R package scran (Lun et al., 2016) to normalize the data. This method works by
declaring a series of cell pools whose expressions are added and normalized against a common reference. Each of these pools is
then interpreted as a linear system from which the contribution of each single cell can be deconvolved, allowing the inference of cell-
wise normalization factors in a way that is robust against noise and low expression levels. To ensure that a majority of genes are not
DE between any of the pools and the common reference that they are normalized against, clusters of homogeneous gene expression
are first built using the function quickCluster. Thus, cell specific normalization factors ni are inferred within each cluster, and then
rescaled by normalization between clusters. Normalization used was:
Enormði; jÞ = log2ð1 + Ecountði; jÞ =niÞ (1)
For the j-th gene in the i-th cell, where ni represent the normalizatiomn factor estimated for the i-th cell.
Correcting for variation in cell cycle in single cell data
Cell cycle numeric scores were inferred for each cell using the function cyclone implemented in package scran (Lun et al., 2016). The
method is based on a pre-defined classifier constituted by gene pairs whose relative difference in expression depends on the cell
cycle stage. By comparing the coherence of the sign of the differences observed in the data to the classifier’s expectation, per-
cell scores were obtained for phases G1 and G2M. These values were summarized as a single numeric score C = (G1-G2M)/
(G1+G2M), whichwemean centered and scaled across cells. These scores were corrected for at the steps of expression data scaling
and cell clustering.
Single cell data scaling
Once the data was normalized in each of the four datasets, we fitted for each gene the following linear model:
E  fpc + fmito + nUMI +C+ ε (2)
The variance associated to the residuals ε derived from this model s2ε was then fitted against mean expression of the corresponding
genes using scran’s smoothing function trendVar (parameters: method = loess, span = 0.1, degree = 2). The deviations from the in-
ferred trend were computed per gene using scran’s function decomposeVar. Then, the first decile corresponding to the genes
showing the largest, negative deviations from the fitted trend were selected, and the procedure was repeated. By doing so, we ob-
tained an unbiased basal trend for the technical component of the residual variance that is not affected by the outliers with variance
much larger than the technical variance. Finally, we calculated the biological component of the variance as the difference between the
residual variance and the basal technical component:
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Once the variance decomposition is ready, the scaled expression ~E was defined by rescaling the residuals ε of Equation (2) by the




By doing this, the mean-variance relationship was successfully removed from the data.
Selection of highly informative genes
Next, we integrated the data corresponding to the different conditions. To do so, we first selected in each case a set of highly infor-
mative genes (HIGs) whose expression is to be interrogated to complete data integration. In both LKS+ and progenitor datasets, we
selected HIGs as those that showed both high levels of (biological) expression variance across cells and had been reported in the
literature as markers of the different cell sub-populations present among LKS+ and progenitor cells (derived from Cabezas-Wall-
scheid et al., 2014, for LKS+ data and Paul et al., 2015, for progenitor cells). Specifically, for LKS+ cells, HIGs were defined as the
intersection between the following four sets of genes: (set i) the 1000 genes with mean expression higher than 0.1 that showed
the largest positive biological variance s2bio across cells in our data (‘‘highly variable genes’’. HVGs); (set ii) genes differently expressed
(10% FDR) between MPPs and HSCs based on the bulk RNA-seq, in all conditions present in each experiment (Table S1, tabs vii-ix,
412 genes), (set iii) genes differently expressed between myeloid progenitors (MPP3) and lymphoid progenitors (MPP4) (219 genes)
based on the bulk RNA-seq data reported in Cabezas-Wallscheid et al. (2014) and (set iv) Genes differentially expressed between
short and long term hematopoietic stem cells (105 genes) based on the bulk RNA-seq data also reported in Cabezas-Wallscheid
et al. (2014). Regarding set (iv), it is important to note that the gating strategy followed in Cabezas-Wallscheid et al. (2014) is slightly
different from ours. While we do not distinguish among sub-types of long-term HSCs (according to our gating strategy, LT-HSCs are
just Flt3-, CD48- and CD150+), Cabezas-Wallscheid et al. (2014) subdivide this population according to CD34 levels, distinguishing
between cells that are Flt3-, Cd48-, CD150+, CD34- (that they denote as HSCs), and cells that are Flt3-,CD48-, CD150+, CD34+ (that
they denote asMPP1s). In what regards short term HSCs, the cell population that they denote MPP2s (Flt3-, CD48+ and CD150+ and
CD34+) would be included within the population described as short-term HSCs in this work (Flt3-, CD48+ and CD150+). Conse-
quently, in order to obtain genes that would mark the difference between LT- and ST-HSCs according to our gating schematics
(set iv), we selected the genes that, at the same time, showed differential expression between HSCs and MPP2 and MPP1 versus
MPP2 in the dataset from Cabezas-Wallscheid et al. (2014) according to their notation.
In what regards the identification of highly informative genes to identify sub-populations in the progenitor cells data, we used the
single cell data published in Paul et al. (2015) where an analogous population of hematopoietic progenitors (c-Kit+ Sca1- Lin-) was
sorted and analyzed using sc-RNaseq. From the dataset reported in this work, we extracted cluster specific fold changes for the
genes showing statistically significant associations to any of the cell clusters reported in the study, and kept those that present,
for some of the clusters, a fold change larger than 1.5 with respect to the average expression levels across the rest of cells in the
dataset. In this case, HIGs were defined as the intersection of these genes and HVGs in our data. Following these procedures,
we selected 349, 115 HIG in the aerosol LKS and progenitor cells, respectively, and 346 and 112 HIGs in LKS and progenitor cells,
respectively, in the secondary engraftment dataset.
Data integration across conditions
Data were integrated across conditions using the anchoring routine proposed in Seurat (FindIntegrationAnchors) (Satija et al., 2015;
Stuart et al., 2019), applied to the sub-matrix constituted by the highly informative genes previously identified. This technique works
by identifying pairs of cells across conditions that represent common cell states (anchors), despite batch/condition effects, that are
then used to provide a transformed (integrated) expressionmatrix Eint where anchors will ultimately be assigned to common cell clus-
ters. The procedure has the advantage of allowing integration over multiple samples at the same time (useful in the engraftment
experiment, where we had to integrate the data across three conditions (PBS, BCG-iv and Mtb-iv), and features flexibility in the
assignment of anchors, allowing for the possibility that some cell types are unique to one of the conditions. After data integration,
the steps of variance modeling, scaling and identification of highly informative genes were repeated on the transformed data, with
a procedure entirely analogous to what was previously described.
Cell clustering
The scaled version of the integrated data was used to identify different cell sub-populations in each of the datasets available. First, we
performed a principal component analysis of the matrix of scaled & integrated expression levels of the HIGs identified from the in-
tegrated data. After visual inspection of elbow plots, we select the first n = 20 PCs (with the exception of LKS cells in the engraftment
experiment for which we selected n = 15) to identify cell clusters using Seurat’s functions FindNeighbors plus FindClusters. We used
the default parameters except for the resolution, which was set at 0.4 for the engraftment experiment and aerosol LKS+ cells, 0.7 for
the aerosol progenitors. In parallel, we run Uniform Manifold Approximation and Projection (UMAP) to visualize the clustering using
RunUMAP, also from Seurat.
Cluster classification and validation of sub-populations (LKS)
To distinguish hematopoietic stem cells (HSC), from multipotent progenitors (MPP), we used the genes differentially expressed be-
tween sorted HSCs and MPPs in the bulk RNA-seq experiments reported in Table S1, tabs vii-ix (set ii, 412 genes). We stratified this
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gene-set according to the direction of the effects and computed in each cell the average integrated scaled expression of all genes
that were respectively up or downregulated in HSCs versus MPPs. By comparing the expression levels of these averaged cell-type
markers across clusters we could classify HSCs and MPPs in each experiment. This allowed the identification of 4 clusters of HSCs
and 2 clusters of MPPs in the aerosol experiment, and 4 HSC and 3 MPP clusters in the second engraftment experiment. (Figures
S3O and S7V, upper panels). Next, to distinguish between myeloid-biased (MPP3) and lymphoid-biased (MPP4) progenitors, we
used the set of 219 genes (set iii) that were reported in Cabezas-Wallscheid et al. (2014) to be differentially expressed between these
two populations according to the direction of effects, and computed the average expression values of these genes (integrated and
scaled) in each cell. Focusing on the clusters previously defined as MPPs, we visualized the expression of these average markers of
lymphoid versus myeloid up or downregulation to distinguish in each experiment, clusters of MPP3 versus MPP4 cells (Figures S3Q
and S7X, center). While in the aerosol experiment we observed one cluster associated to each phenotype, in the second engraftment
we identified two clusters of MPP3s and one cluster of MPP4s. Finally, in order to distinguish short versus long term HSCs, we built
analogous average markers from the set of genes differentially expressed between these two cell sub-types as defined by Cabezas-
Wallscheid et al. (2014). Exploring the distribution of these average markers across HSC clusters led to the identification of a marked
distinction between one LT- versus three ST-HSCs in the aerosol experiment, and a more gradual distribution of transcriptional pro-
files, which can be associated to the existence of two versus two clusters of LT- versus ST-HSCs in the second engraftment dataset
(Figures S3O and S7V, bottom)
Cluster classification and validation of sub-populations (progenitor populations)
In order to identify subpopulations of myeloid progenitors associated to the different developmental stages and lineage biases pre-
sent in the cell population initially sorted (c-Kit+ Sca1- Lin-), we capitalized in the data published in Paul et al. (2015), where the same
cell population was analyzed through scRNA-seq. In that work, the authors identified 19 clusters that they associate to either Com-
mon myeloid progenitors (CMPs), Granulocyte-Monocyte progenitors (GMPs) or Megakaryocyte-erythrocyte progenitors (MEPs).
Within each of these broader groups, they further identified subpopulations that were polarized toward specific cell fates: CMPs
biased toward a megakaryocytic cell fate, groups of MEPs distributed in a continuous gradient of bias toward erythrocyte differen-
tiation, as well as CMPs and GMPs showing bias toward different myeloid cells: monocytes, neutrophils, eosinophils and basophils.
As part of their analyses, they report a set of 3,461 genes that are specific markers of each of these clusters, providing an expression
estimate of the gene in each cluster, measured as the fold change of the observed expression of a given gene, in a given cluster,
compared to its average expression across all clusters.
In order to compare these data to our clustering results, we selected the subset of their cluster markers that were among the set of
HIGs in the integrated data. Then, we retrieved, for each of these genes, cluster-specific expression estimates by fitting a linearmodel
~Eint  0+Cluster (5)
Which produced a cluster specific intercept boði; jÞ, for the ith gene under scrutiny, in the jth cluster. From these cluster-specific in-
tercepts, (which operate in log-scale) we reversed the log-transformation to retrieve a natural scale expression estimate for the
expression of gene I in cluster j as 2boði;jÞ, which we averaged across clusters for each gene: C2boði;jÞDj. Finally, by obtaining the ratio
between those two quantities, we retrieved an estimate of the expression fold change of any given cluster with respect to the average
of all clusters.
FCði; jÞ = 2boði;jÞC2boði;jÞDj (6)
These values are equivalent to the fold changes reported in Paul et al. (2015) and were used to identify matches between our cell
clusters and those reported by Paul et al. (2015) based on the correlation structure of the two datasets (Figure S3P and S7W).
Cell clustering assignment was further validated by inspecting the expression levels of canonical lineage markers (Figures S3Q
and S7X). MEP expressed Car1, Car2, Klf1 high; CD34, Cebpa, and Spi1 low; GMPs expressed Car1, Car2, Klf1 low, CD34, Cebpa,
Spi1 high; and CMPs expressed Meis1 high while GMP and MEP markers were lowly expressed.
WithinMEP cells, we further analyzed a series ofmarkers that were reported to either increase or decrease continuously in earlier or
more mature erythrocyte progenitors (Car1, Car2, Cited4, Epor, Gfi1b, Klf1, and Phf10; whose expression increases in more mature
cells, and Gata2 and Meis1, which decreases). As it was observed in Paul et al. (2015) our clusters of erythroid progenitors can be
mapped to different developmental stages, from MEP_EP1 (earlier) to MEP_EP3 (more mature).
Within GMPs, neutrophil progenitors (GMP_NPs) were characterized by high expression levels of neutrophilic markers Cebpe and
Gfi1; basophil progenitors (GMP_BPs) by high expression of basophile marker Lmo4; and Monocyte progenitors (GMP_MonP) by
high amounts of Irf8.
Within-cluster differential gene expression induced by BCG and Mtb
Finally, we interrogated for differences in expression of genes in response to BCGorMtb challenges. Since one of the putative effects
of BCG and/orMtb on cell phenotypes might be the promotion or arrest of cell quiescence, we used a linear model where cell cycle is
not corrected for, in order to avoid masking the putative effects of treatment on the expression patterns of cell cycle-dependent
genes. It is also important to note, that to avoid the distortion induced in the data by the procedures of data scaling and integration,
to conduct differential expression analyses, we used the normalized, original data prior to these procedures used in cell clustering. To
do these analyses, we fitted the following experimental design:
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E  fpc + fmito + nUMI +Cluster +Condition : Cluster + ε (7)
The results of these analyses, for each cluster, are reported in Tables S4, S5, and S6 and summarized in Figures 3 and 7, evidencing
the existence of relevant effects within each of the cell clusters identified, in the four datasets here analyzed.
GO enrichments and visualization
Gene ontology (GO) enrichment analyses were performed using the Cytoscape module ClueGO (Bindea et al., 2009; Shannon et al.,
2003). We conducted one-sided tests for enrichment and corrected for multiple tests using the Benjamini-Hochberg (B-H) method
(Benjamini and Hochberg, 1995). For visualization, in Figure S2B and the Table S2 (bulk RNA-seq data) and Table S7 (serial engraft-
ment experiment, sc-RNA-seq data), analyses were focused only on terms that fell between levels 4 and 7 of the GO tree in the (Bio-
logical Process). In all analyses, we included terms that had at least 10 genes in the test gene-set and for which at least 20% of the
total number of genes belonging to the GO term were present in the test gene set, except in the case of bulk-RNA-seq MPPs, where
thresholds were raised to a minimum of 15, and 35%. Finally, to compile Figure S2A, which shows the existing correlation between
GO-enrichment results after BCG versusMtb treatments in each cell type, analyses were repeated removing the thresholds on gene-
set size or percentage in order to avoid any selection bias. In this analysis we included all terms between levels 4 and 7 of the GO tree,
regardless of enrichment significance or gene-set size. Importantly, when done, a much larger number of GO terms passed the
enrichment significance threshold (between 1.4 and 7.1 times more terms enriched at 5% FDR, depending on the combination of
cell-type and treatment), despite the much larger set of terms tested.
Finally, GSEA (https://www.gsea-msigdb.org/gsea/) was used to interrogate functional enrichments among genes showing differ-
ences in expression between BCG andMtb treated mice, in each cell type (Figure 2D; Table S3). It was again used to interrogate for
functional enrichments among genes differentially expressed upon treatment, either Mtb alone in the aerosol challenge experiment
Figure 3S), or both BCG andMtb in the serial engraftment section (Figures 7T and 7U). In all cases, we used the hallmark list of gen-
esets, and conducted GSEA on ranks of standardized differences in expression, (mode GSEA pre-ranked, version 6.2).
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Supplemental Figures
(legend on next page)
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Figure S1. Gating Strategy for HSCs and Progenitors and Their Kinetics Post-infection, Related to Figure 1
(A) Cells were gated for FSC-A against SSC-A. Doublets were excluded using FSC-H against FSC-A. Viable cells were gated and lineage-committed cells were
excluded.Within the lineage-negative population, cells were gated as LKS-defined as double positive for cKit and Sca-1. Gated on the LKS population, cells were
divided into LT-HSC, ST-HSC andMPP based on CD150 and CD48 expression. MPPswere characterized asMPP3 orMPP4 by their surface expression of CD34
and Flt3. In a second strategy, lineage negative cells were gated based on CD127+ and CD127-. Lin- CD127- population was further defined by Sca-1 and c-Kit.
c-Kit+ Sca-1- cells were further gated based on CD34 andCD16/32 to define CMP, GMP andMEP. Lineage- and CD127+ cells are defined as CLPs based on Sca-
1lo and c-Kitlo expression. Finally, in another set of experiments, Lineage+ cells and then Sca-1+ cells were excluded. The remaining cells were further subdivided
into cKit+ CD16/32+ and cKit+ CD16/32- groups. In the cKit+ CD16/32- group, CD34+ Flt3+ cells were denoted asMDP by being CD115+ but Ly6C-. cKit+CD16/32+
cells were further gated on CD34+ Flt3- cells. Within this fraction, Ly6C+ CD115- cells were the GP and Ly6C+ CD115+ were cMoP. (B-D) Kinetics of the frequency
among single viable BM cells (top panel) and total cell counts (bottom panel) of LT-HSC, ST-HSC,MPP3/MPP4 in the BMof BCG-iv vaccinated orMtb-iv infected
mice. (E) BM cells from WT mice were infected with BCG-GFP or H37Rv-GFP for 4 hours in vitro (MOI 3). ImageStream analysis of H37Rv-GFP infection (top
panel) and BCG-GFP (bottom panel) in Lin- cKit+ Sca-1- progenitors. (F-H) Mice were intravenously infected with 1x106 CFU of BCG, Mtb or Mtb-DRD-1 for
28 days. Frequency of LKS in each group (F) and HSC/progenitor subsets of BCG versusMtb-DRD-1 (G), orMtb versusMtb-DRD-1 (H; left panel frequency, right
panel total cell counts). (I-O) 1x106 CFU of BCGorMtbwere delivered intravenously for 28 days. Percentage ofMDP (I), cMoP (J), GP (K) and Ly6Chimonocytes (L)
and frequency and total numbers of neutrophils (M) in the BM. (N-O) Frequency and total LKS cells (N), as well as the frequency and total cell number of the HSC/
progenitor fractions in BCG versusMtb-infected mice in the spleen after 28 days (O). Differences assessed by Two-tailed Student’s T-Test for each individual cell
population in B-D and G-O or One-way ANOVA followed by Tukey’s Multiple Comparisons Test in F.
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Figure S2. HSC Imprinting by BCG and Mtb-i.v. and Subsequent Anti-mycobacterial Responses by Macrophages to Mtb Infection In Vitro,
Related to Figure 2
(A) Scatterplot for significance levels (-log10(p value) of gene ontology enrichment analyses conducted among DE genes upon BCG versusMtb infections in HSC
(left) andMPP (right). (B) Gene ontology terms enriched among DEG in response toMtb in MPP (at FDR < 0.01). (C-F) BMDM fromPBS control, BCG-iv andMtb-iv
groupswere generated. Purity of BMDMcultures as determined by flow cytometry using expression of BMDMmarkers CD11b and F4/80 (C). Activation ofmature
BMDMwas assessed by flow cytometry viaMFIs of CD80 (D), CD40 (E) andMHC-II (F) with representative histograms in the top panels. Model of in vivo antibiotic
treatment (G). BMDM-derived from the BM cells of these mice were infected with Mtb (H37Rv; MOI 1) and the number of CFU was determined at different time
points after infection (H). (I) BMDM CFU prior to intratracheal transfer, as detailed in Figures 2H and 2I. Differences determined by One-way ANOVA followed by
Tukey’s Multiple Comparisons Test in C-F and I; Two-way ANOVA followed by Tukey’s Multiple Comparisons Test in H.
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Figure S3. HSC and Progenitor Kinetics following Aerosolized Mtb Infection, Related to Figure 3
(A-M) WT mice were infected with aerosolized Mtb. (A) Day 1 lung CFU following aerosol infection. (B-H) Kinetics of the frequencies among BM cells of LT-HSC
(B), ST-HSC (C), MPP (D), MPP3/MPP4 (E), CMP (F), GMP (G), CLP (H) inMtb infected WT mice. (I) Total cell counts of cMoPs in the BM of WT mice at 120 days
(legend continued on next page)
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post-infection. Kinetics of the frequencies and total numbers of neutrophils and Ly6Chi monocytes in the BM (J-K) and lung (L-M) as well as the frequencies and
total cell counts of adaptive CD8 and CD4 T cells in the lung (N). (O) Average expression of cell-type markers across clusters. (P) Correlations between genome-
wide expression patterns of our myeloid progenitor data and results published by Paul et al. (2015). In each column, Spearman correlations are normalized to
cover the range [0-1]. Blue boxesmark the best fit (i.e., candidate identity match) for each of our clusters. (Q) Expression patterns across clusters for somemarker
genes associated to commitment to the different lineages characterized in this study. (R) Proportion of cells per cluster in both sub-populations (LKS andmyeloid
progenitors), for cells coming fromPBS versusMtb treatedmice. (S) Fisher exact test enrichments (log2 odds ratios) for the fraction ofMtb cells in each cluster. (T)
Number of PBS versus Mtb cells in each cluster. (U) Genome wide correlation of Mtb effect sizes (logFC) across clusters. Statistics were (B-H, J-N) One-way
ANOVA followed by Tukey’s Multiple Comparisons Test with significance shown compared to day 0 or day 1 post-infectionmice for each cell type and Two-tailed
Student’s t test (I).
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Figure S4. IFN-I Signaling Impairs Myelopoiesis, Related to Figure 4
(A-C) WT and Ifnar1/ mice were infected with 1x106 Mtb-iv. Kinetics of the frequencies among single viable BM cells of CMP (A), GMP (B) and CLP (C). (D-F)
mice were infected with Mtb via the aerosol route. Percentages of CMP (D), GMP (E) and CLP (F) in the BM at day 60. (G) Active IFN-I was measured in the BM
collected after 12, 24, and 36 hours after Poly (I:C) treatment. (H-Q) WT and Ifnar1/ mice were treated with Poly (I:C), or PBS, at day 0, 2, 4, 6. Frequencies
among single viable BMcells of LT-HSC (H), ST-HSC (I), MPP (J), CMP (K) and CLP (L) at days 0, 3 and 7, as well as the total number of MDP (M), cMoP (N), GP (O),
Ly6Chimonocytes (P) and neutrophils (Q) at day 3 post-Poly-(I:C) treatment. (R-X)WTmice were treatedwith b-glucan at day 0 and day 3. Frequencies among BM
(legend continued on next page)
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cells (left panel) and total cell counts (right panel) of LKS (R), LT-HSC (S), ST-HSC (T), MPP (U), CMP (V), GMP (W) andCLP (X) in PBS (day 0) or b-glucan i.p. at day
7 post-treatment. Differences determined by Two-way ANOVA followed by Sidak’s Multiple Comparisons Test in A-C, H-Q, Two-Tailed Student’s T-Test in D-F,
One-way ANOVA followed by Dunnett’s Multiple Comparisons Test in G and Non-Parametric Mann-Whitney Test R-X.
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Figure S5. The IFN-I/Iron Axis Regulates Cell Death of Myeloid Progenitors, Related to Figure 5
Frequency of necrotic (NucSpot+ AnnexinV-) CLP (A) in the BM of BCG-iv andMtb-iv infected mice at day 7. (B-D) Frequency among single viable BM cells (left
panels) and total cell counts (right panels) of CMP (B), GMP (C), CLP (D) of naiveWT andRipk3/mice. (E) Frequency among BMcells of CLP inWT andRipk3/
Mtb-iv infected mice at day 7. (F) Frequency of CLP with disrupted mitochondria in the BM of BCG-iv and Mtb-iv infected mice at day 7. (G) Relative levels of
mitochondrial iron (Fe2+) in CLP of BCG-iv andMtb-iv infectedmice at day 7. (H) Representative histogram of expression of CD71 (left panel) and quantification of
CD71 expression (right panel) on CLPs in the BM of Mtb-iv infected WT and Ifnar1/ mice at day 28. (I) Expression of CD71 on CLPs in the BM of WT and Poly
(I:C)-treated WT and Ifnar1/ mice. (J) Relative proportion of mitochondrial iron dye (Fe2+) in the CLP of Poly (I:C)-treated WT and Ifnar1/ mice. Frequency of
CLPs with a disrupted mitochondrial potential (K), high mitochondrial ROS (L), or those that are necrotic (M). Differences were assessed via One-way ANOVA




Figure S6. Loss of Iron Homeostasis Disrupts Myelopoiesis, Related to Figure 6
(A) Frequency (left panel) and total cell count (right panel) of CLP in FthD/D, R26cre or Fthlox/lox mice as generated in Figure 6A. (B-G) BM-Fth+/+ or BM-Fth/
chimeric mice were generated as described in Figure 6D. Frequency (left panel) and total cell count (right panel) of CLP in BM-Fth+/+ or BM-Fth/ chimeric mice
(B). (C) Relative percentage of iron (Fe2+) specific dye in the mitochondria of CLP in the BM of BM-Fth/ compared to BM-Fth+/+ mice. (D) BCG CFU (infection at
MOI 10) in BMDM from BM-Fth+/+ or BM-Fth/ mice at the indicated time points. CFU in the liver (E) and spleen (F) following 28 days of aerosol Mtb infection.
Frequency of myeloid cell populations in the lung (G), BM (H) and spleen (I) of naive BM-Fth+/+ and BM-Fth/ mice. Differences assessed by One-way ANOVA




Figure S7. Mtb-Imprinted HSCs Have Impaired Engraftment for up to at Least 1 Year Post-exposure, Related to Figure 7
(A-K) Mixed chimeric mice were generated as described in Figure 7A. At 4-week intervals post-reconstitution, peripheral blood was sampled. Percentages of
CD45.1+ versus CD45.2+ leukocytes (A), Ly6Chi monocytes (B), neutrophils (C) or T cells (D) in the blood. At 16 weeks post-reconstitution, BCG:Mtb mixed
(legend continued on next page)
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chimera mice were sacrificed. Frequency of total BMCD45 (E), CCR2+ monocytes (F), or neutrophils (G), as well as pulmonary leukocytes (H), CCR2+monocytes
(I), neutrophils (J) and macrophages (K). (L-R) Secondary engraftment experiments were performed as in Figure 7K.Mtb CFU in the BM cells prior to secondary
engraftment (L). In the peripheral blood, total cell counts of CD11b+ cells (M), Ly6Chi monocytes (N) and neutrophils (O), as well as BM LKS (P), LT-HSC (Q) and
CMP (R) frequencies. (S-T) UMAP dimensionality reduction plots for LKS and myeloid progenitor cells, respectively, for the serial engraftment experiment. (U)
Schematic hematopoietic tree diagram showing the approximated position of the different clusters identified (cluster specific color code common to panels S-T).
(V) Average expression of cell-type markers across clusters. (W) Correlations between genome-wide expression patterns of our myeloid progenitor data and
results published by Paul et al. (2015). In each column, Spearman correlations are normalized to cover the range [0-1]. Blue boxes mark the best fit (i.e., candidate
identity match) for each of our clusters. (X) Expression patterns across clusters for some marker genes associated to commitment to the different lineages
characterized in this study. (Y) Genome wide correlation of Mtb versus BCG effect sizes (logFC) in each cluster. Differences measured via Two-Way ANOVA
followed by Sidak’s Multiple Comparison Test (A-D), Student’s Two-tailed T-Test (E-K) and One-Way ANOVA followed by Tukey’s Multiple Comparisons Test in
(M-R). In A-D, only significant differences at 16 weeks were labeled.
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